



## SCL, LMO1 and Notch1 Reprogram Thymocytes into Self-Renewing Cells

Bastien Gerby, Cédric S. Tremblay, Mathieu Tremblay, Shanti Rojas-Sutterlin, Sabine Herblot, Josée Hébert, Guy Sauvageau, Sebastien Lemieux, Eric Lecuyer, Diogo Veiga, et al.

### ► To cite this version:

Bastien Gerby, Cédric S. Tremblay, Mathieu Tremblay, Shanti Rojas-Sutterlin, Sabine Herblot, et al.. SCL, LMO1 and Notch1 Reprogram Thymocytes into Self-Renewing Cells. PLoS Genetics, 2014, 10 (12), pp.e1004768. 10.1371/journal.pgen.1004768 . hal-02353324

**HAL Id: hal-02353324**

**<https://hal.science/hal-02353324>**

Submitted on 6 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# *SCL*, *LMO1* and *Notch1* Reprogram Thymocytes into Self-Renewing Cells

Bastien Gerby<sup>1,2,3</sup>, Cedric S. Tremblay<sup>1,2,3,4</sup>, Mathieu Tremblay<sup>1,2,3</sup>, Shanti Rojas-Sutterlin<sup>1,2</sup>, Sabine Herblot<sup>1,2,3</sup>, Josée Hébert<sup>1,2,3</sup>, Guy Sauvageau<sup>1,2,3</sup>, Sébastien Lemieux<sup>1,2</sup>, Eric Lécuyer<sup>4,5</sup>, Diogo F. T. Veiga<sup>1,2</sup>, Trang Hoang<sup>1,2,5,6\*</sup>

**1** Institute of Research in Immunology and Cancer – University of Montreal, Montreal, Quebec, Canada, **2** Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada, **3** Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, **4** Clinical Research Institute of Montreal (IRCM), Montreal, Quebec, Canada, **5** Department of Biochemistry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada, **6** Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

## Abstract

The molecular determinants that render specific populations of normal cells susceptible to oncogenic reprogramming into self-renewing cancer stem cells are poorly understood. Here, we exploit T-cell acute lymphoblastic leukemia (T-ALL) as a model to define the critical initiating events in this disease. First, thymocytes that are reprogrammed by the *SCL* and *LMO1* oncogenic transcription factors into self-renewing pre-leukemic stem cells (pre-LSCs) remain non-malignant, as evidenced by their capacities to generate functional T cells. Second, we provide strong genetic evidence that *SCL* directly interacts with *LMO1* to activate the transcription of a self-renewal program coordinated by *LYL1*. Moreover, *LYL1* can substitute for *SCL* to reprogram thymocytes in concert with *LMO1*. In contrast, inhibition of *E2A* was not sufficient to substitute for *SCL*, indicating that thymocyte reprogramming requires transcription activation by *SCL-LMO1*. Third, only a specific subset of normal thymic cells, known as DN3 thymocytes, is susceptible to reprogramming. This is because physiological *NOTCH1* signals are highest in DN3 cells compared to other thymocyte subsets. Consistent with this, overexpression of a ligand-independent hyperactive *NOTCH1* allele in all immature thymocytes is sufficient to sensitize them to *SCL-LMO1*, thereby increasing the pool of self-renewing cells. Surprisingly, hyperactive *NOTCH1* cannot reprogram thymocytes on its own, despite the fact that *NOTCH1* is activated by gain of function mutations in more than 55% of T-ALL cases. Rather, elevating *NOTCH1* triggers a parallel pathway involving *Hes1* and *Myc* that dramatically enhances the activity of *SCL-LMO1*. We conclude that the acquisition of self-renewal and the genesis of pre-LSCs from thymocytes with a finite lifespan represent a critical first event in T-ALL. Finally, *LYL1* and *LMO1* or *LMO2* are co-expressed in most human T-ALL samples, except the cortical T subtype. We therefore anticipate that the self-renewal network described here may be relevant to a majority of human T-ALL.

**Citation:** Gerby B, Tremblay CS, Tremblay M, Rojas-Sutterlin S, Herblot S, et al. (2014) *SCL*, *LMO1* and *Notch1* Reprogram Thymocytes into Self-Renewing Cells. PLoS Genet 10(12): e1004768. doi:10.1371/journal.pgen.1004768

**Editor:** H. Leighton Grimes, Cincinnati Children's Hospital Medical Center, United States of America

**Received:** February 11, 2014; **Accepted:** September 22, 2014; **Published:** December 18, 2014

**Copyright:** © 2014 Gerby et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The infrastructure of IRIC is supported in part by a group grant from the Fonds de Recherche du Québec en Santé (FRQS, <http://www.frsq.gouv.qc.ca/fr/index.shtml>) and the Quebec Leukemia Cell Bank (JH) by the Cancer Network of the FRQS. This work was funded by grants from the Canadian Institutes for Health Research (CIHR, <http://www.cihr-irsc.gc.ca/e/193.html>), the Canadian Cancer Society Research Institute (CCSRI, <http://www.cancer.ca/Research.aspx>) (TH, GS, EL), the Leukemia Lymphoma Society of Canada (<http://www.llscanada.org/aboutllsc/>), the Cancer Research Society Inc (<http://www.crs-src.ca/>) and the MERST Québec (<http://www.merst.gouv.qc.ca/>) (TH), the Canada Research Chair program (<http://www.chairs-chaire.gc.ca/home-accueil-eng.aspx>) (GS) and by studentships from the Cole Foundation (<http://colefoundation.ca/>) (BG, MT and DFTV), CIHR (MT), CCSRI (CST), FRQS (SRS, MT) the Molecular Biology program (MT) and the Jean-Guy Mongeau Foundation (SRS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors declare no competing financial interest.

\* Email: [trang.hoang@umontreal.ca](mailto:trang.hoang@umontreal.ca)

¶ These authors contributed equally to this work.

¶a Current address: Australian Centre for Blood Diseases (ACBD), Monash University, Melbourne, Victoria, Australia

¶b Current address: Pediatrics Department, Faculty of Medicine, University of Montreal, and Charles-Bruneau cancer centre, Sainte-Justine Hospital, Montréal, Québec, Canada

## Introduction

An important attribute of stem cell populations is the capacity to self-renew indefinitely both in normal development and during the process of cell transformation. Cancer stem cells, initially identified in acute myeloblastic leukemias [1], can self-renew indefinitely to propagate and maintain the disease [2]. This led to the experimental definition of leukemia initiating cell (LIC) characterized by their capacities to initiate the disease in transplanted

host mice [1,3]. Important questions remain to be resolved with regards to the nature of the cell of origin of cancer, that is the normal cells from which cancer originates [4–6] and the mechanisms that drive the transition to an initiated state [7]. It was initially thought that the capacity for self-renewal of LICs, also referred to as leukemic stem cells (LSCs), is conferred by the cell of origin of cancer, that is, primitive hematopoietic stem/progenitor cells (HSPCs), even though the leukemic phenotype is manifest in differentiating myeloblasts [3]. Alternatively, oncogenes acting on

## Author Summary

Deciphering the initiating events in lymphoid leukemia is important for the development of new therapeutic strategies. In this manuscript, we define oncogenic reprogramming as the process through which non-self-renewing progenitors are converted into pre-leukemic stem cells with sustained self-renewal capacities. We provide strong genetic evidence that this step is rate-limiting in leukemogenesis and requires the activation of a self-renewal program by oncogenic transcription factors, as exemplified by *SCL* and *LMO1*. Furthermore, *NOTCH1* is a pathway that drives cell fate in the thymus. We demonstrate that homeostatic *NOTCH1* levels that are highest in specific thymocyte subsets determine their susceptibilities to oncogenic reprogramming by *SCL* and *LMO1*. Our data provide novel insight into the acquisition of self-renewal as a critical first step in lymphoid cell transformation, requiring the synergistic interaction of oncogenic transcription factors with a cellular context controlled by high physiological *NOTCH1*.

committed progenitors can induce a stem cell gene signature [8], leading to the reprogramming of non-self-renewing progenitors into pre-leukemic stem cells (pre-LSCs) [9,10]. Nonetheless, only subsets of progenitors are susceptible to oncogenic reprogramming, raising questions on the molecular events that determine the susceptibility of target cells to oncogenes.

Normal thymic progenitors have limited if any self-renewal capacity [11,12]. Bone marrow-derived progenitors settle in the thymus and gradually acquire T cell characteristics while losing “stemness” [13]. The *NOTCH1* pathway is a master regulator of thymopoiesis acting at several steps, in particular at the DN3 stage where *NOTCH1* together with the pre-TCR drives irreversible T-lineage commitment [14]. *NOTCH1* gain-of-function mutations were found in more than half of human T-ALL [15] and in most mouse models [16,17]. The significance of *Notch1* for oncogenic transformation has been well established whereas the role of *Notch1* in hematopoietic stem cell (HSC) self-renewal has been controversial (reviewed in [18]). *NOTCH* activity is highly context-dependent [19]. Hence, a hyperactive *Notch1* allele (*NICD*; hereafter referred to as the *Notch1* oncogene) is shown to cause an exhaustion of HSCs at the expense of T-LSCs [20]. Once transformed, LICs in *Notch1*-induced T-ALL depend on continued *Notch1* signals for maintenance [15,21–23] and on several downstream effectors that include *Hes1* [24–28] and *Myc* [27,29]. These LICs were found in the immature single positive (ISP8) population, raising the question whether or not ISP8 are the cell of origin of T-ALL. Moreover, *Notch1* is a weak tumor initiator [30]. Finally, the importance of *Notch1* in pre-LSCs remains to be clarified.

Self-renewal in normal HSCs is controlled by a network of transcription factors [31]. This network includes the basic helix-loop-helix (bHLH) transcription factors *SCL*/*TAL-1* [32,33] and the highly homologous *LYL1* [34]. Both *SCL* [35] and *LYL1* form DNA binding heterodimers with E-proteins (e.g. *E2A* and *HEB*) that are also bHLH factors and directly interact with nuclear co-factors LIM-only (LMO) proteins to form transcription complexes that drive lineage-specific gene expression in hematopoietic cells [36,37]. *SCL* is partly redundant with *LYL-1* in HSCs [34]. *SCL*, *LYL1* and *LMO1/2* expression decreases drastically at early stages of T-cell differentiation [13]. Their ectopic expression in the thymus, commonly driven by chromosomal rearrangements, is associated with T-ALL [38].

Overexpression of *LMO1* or *LMO2* in the thymus induces leukemia in mice with low penetrance and long latency [39]. This results from the emergence of pre-LSCs with altered gene expression [9]. Strikingly, T-ALL onset is accelerated by genetic collaboration with *SCL* [40,41]. How *SCL* induces T-ALL remains to be clarified. Indeed, two mechanisms have been proposed for *SCL*-mediated leukemogenesis. *SCL* heterodimerizes with and inhibits the activity of E-proteins [42–44] [45–47], in particular of *E2A* and *HEB* that are nodal regulators in the T lineage (reviewed in [48,49]). Accordingly, *SCL* inhibitory activity is sufficient to cause differentiation arrest in both B- [50] and T lineages [51]. Inhibition of E protein and differentiation blockade were, however, insufficient for leukemogenesis since most *SCL* transgenic lines did not develop T-ALL [40,51,52], with the exception of one transgenic model [53,54]. In parallel, inhibitor of DNA-binding *ID1* that sequesters *E2A*/*HEB* away from DNA was found to induce T-ALL in transgenic mice [55]. This led to the current view that bHLH oncogenic transcription factors that include *SCL* (or *TAL1*), *TAL2* and *LYL1* form inactive transcriptional complexes that induce T-ALL via inhibition of E proteins (reviewed in [49,56]). With the predicament that cancer development is a Darwinian evolutionary process, the natural selection for genetic variants in which E proteins are inhibited should involve a variety of mechanisms, upregulation of bHLH transcription factors, of *ID1-4* proteins that sequester E proteins away from DNA and/or inactivation of E protein encoding genes. The absence of the two latter categories so far in human T-ALL samples argues in favor of the second hypothesis, that transcription activation by oncogenic bHLH factors is an important leukemogenic driver. In support of this hypothesis, there is evidence for target gene activation in leukemic T cells [9,57–60]. Nonetheless, how the *SCL*-*LMO1/2* collaboration establishes a pre-leukemic state to initiate T-ALL remains ill-defined. Recently, *Lyl1* gene invalidation is shown to abrogate *LMO2* self-renewal activity in pre-LSCs, suggesting that *Lyl1* is an important downstream target of *LMO2* [61]. However, overexpressing *LYL1* on its own is clearly insufficient for thymocyte reprogramming [9], indicating that the molecular context for cell transformation and/or thymocyte reprogramming by *LYL1* remains to be uncovered. The inability of *SCL* or *LYL1* to induce T-ALL on their own and the long latency required for *LMO1/2*-induced leukemogenesis strongly support the view that oncogene cooperativity drives synergistic modulation of gene expression, associated with major change in cellular reorganization [62]. Understanding the process of oncogene cooperativity in leukemia initiation can reveal mechanisms that control the growth of leukemic stem cells [63].

Recent genome-wide studies of leukemic samples at diagnosis have been highly informative on the mutational process and potential driver mutations in acute leukemias [64,65]. These powerful approaches did not allow for a clear distinction between initiating events in leukemogenesis and collaborating events that contribute to disease progression, which were revealed through two distinct approaches, the study of rare monozygotic twins [10] or of mouse models. Major questions remain nonetheless to be investigated. For example, it is not clear what determines the nature of the target cells of oncogenic reprogramming [5].

We used converging genome-wide approaches together with molecular and genetic approaches to provide novel evidence how the necessary collaboration between *SCL*, *LMO1* and *Notch1* determines the target cells of transformation in T-ALL and to identify novel mechanisms by which these oncogenes cooperate to activate stem cell genes and to convert normal thymocytes into self-renewing pre-LSCs. In particular, transcription activation posits a requirement for direct *SCL*-*LMO1* interaction to

assemble transcription activation complexes at target loci. In the present study, we generated transgenic mice expressing a mutant *SCL* that is unable to associate with *LMO1/2* but retains its capacity to inhibit E2A/HEB, to provide genetic evidence for the importance of transcription activation in thymocyte reprogramming and in leukemogenesis.

## Results

### *SCL* and *LMO1* oncogenes confer an aberrant self-renewal to DN3 pre-leukemic thymocytes

The capacity for sustained self-renewal is best observed in serial transplantation assays. While normal thymocytes did not engraft in transplanted hosts, *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes afforded thymic reconstitution which was sustained through three serial transplantations (**Fig. 1A–C**). Thymocyte differentiation in the thymus progresses from the double negative stages (DN1–4) to the CD4<sup>+</sup>CD8<sup>+</sup> double positive (DP) stage and finally mature single positive CD4<sup>+</sup> (SP4) or CD8<sup>+</sup> (SP8) cells (**S1A,B Fig.**). In primary and secondary transplantation, donor-derived cells retained a capacity to give rise to DP cells. However, after the tertiary transplantation, the proportion of donor-derived DN3 thymocytes increased markedly (**Fig. 1B**), resulting in a cumulative 75-fold amplification (**Fig. 1C**). In contrast, the other thymocyte subsets decreased during the same time-frame. We transplanted purified ETP, DN1–4 and DP populations from pre-leukemic *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice (**Fig. 1D**). Only purified DN3 cells efficiently engrafted the thymus of recipient mice, (*left panel*). A fraction of mice transplanted with DN1 and DN2 cells exhibited less than 1% engraftment and were “negative” by definition, although this was different from the absence of engraftment from DP cells. Furthermore, purified DN3 thymocytes retained the capacity to differentiate *in vivo* into DP and SP cells and, at the same time, to expand and self-renew (*right panel*).

Interestingly, donor-derived SP4 or SP8 thymocytes recovered from transplanted mice were activated by TCR stimulation to the same extent as normal host thymocytes by upregulating the CD69 activation marker (**Fig. 1E**). This indicates that engrafted *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes were non-leukemic. Accordingly, transplanted mice remained aleukemic, with small thymi and normal spleen size, despite the elevated expansion of DN3 thymocytes (**S1C Fig.**). Together, our results indicate that the *SCL* and *LMO1* oncogenes reprogram DN3 thymocytes into pre-LSCs that have acquired de novo self-renewing activity and retained their capacity to differentiate into functional T cells.

### The activity of *SCL*-*LMO1* in DN3 thymocytes is sensitive to NOTCH levels

The DN3 stage in the thymus marks T-lineage commitment driven by NOTCH1 acting in concert with the pre-TCR. We therefore addressed the question whether these two pathways contribute to DN3 cell reprogramming by *SCL*-*LMO1*. We first addressed the functional importance of NOTCH1 in this process by lowering or increasing NOTCH activity. The expansion of pre-leukemic *SCL*-*LMO1* DN3 cells was recapitulated *in vitro* by co-culture on OP9 stromal cells expressing the NOTCH ligand Delta-like-1 (OP9-DL1) [66] (**Fig. 2A**). DAPT, an inhibitor of the -secretase, abrogated this expansion (**Fig. 2A**) without affecting the viability of the OP9-DL1 stromal cells (**S2 Fig.**). Strikingly, DAPT-treated DN3 cells were no longer able to engraft compared to control cells exposed to the vehicle alone when transplanted at equal numbers, suggesting that physiologic Notch1 signaling is required for *SCL*-*LMO1* activity. We then addressed the consequences of supraphysiologic *Notch1* signaling on thymocyte

reprogramming. Oncogenic *Notch1* has well established functions in leukemia induction and leukemia maintenance (reviewed in [18]). Nonetheless, the role of *Notch1* during this initial transition stage from a cell with finite life span to an aberrantly self-renewing pre-LSC remains to be addressed. Surprisingly, pre-leukemic *Notch1*<sup>tg</sup> thymocytes did not repopulate the thymus of recipient mice (**Fig. 2B**). Rather, *Notch1* significantly enhanced the engraftment of *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes (**Fig. 2B**). These cells also became independent of the thymic microenvironment (**S3A–B Fig.**). Therefore, *Notch1* acts as a strong enhancer of *SCL*-*LMO1* self-renewal activity but lacks intrinsic reprogramming activity in the absence of other oncogenic transcription factors.

### *Notch1* oncogene confers a proliferative advantage to *SCL*-*LMO1*-induced pre-LSCs independently of a functional pre-TCR


To determine whether the *Notch1* oncogene modifies the frequency of *SCL*-*LMO1* pre-LSCs and/or their expansion at the clonal level, we performed limiting dilution assays using DN3 pre-leukemic thymocytes (**Fig. 2C**). A hyperactive *Notch1* allele increased by 60-fold the frequency of *SCL*-*LMO1*-induced pre-LSCs (**Fig. 2C**). In contrast, *Notch1* did not significantly modify the expansion potential of individual pre-LSC when transplanted at ~1 competitive repopulating unit, (**S3C Fig.**). Therefore, *Notch1* expands the pool of *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-LSCs *in vivo*. We took advantage of the *Tcrβ* gene rearrangement as a clonal marker to assess the diversity of pre-LSCs in transplantation assays (**S3D Fig.**). Pre-leukemic thymocytes were polyclonal before transplantation. Engrafted *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes exhibited an oligoclonal signature whereas *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes remained polyclonal after transplantation. Furthermore, we ruled out the possibility that *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes had acquired *Notch1* mutations (**S1 Table**). These results indicated that a limited number of *SCL*-*LMO1* expressing clones were able to self-renew in the absence of *Notch1* while multiple clones were able to self-renew in the presence of *Notch1*.

We next addressed the role of the pre-TCR in the self-renewal activity induced by *SCL*-*LMO1* and *Notch1*. We exploited the *Cd3ε*<sup>-/-</sup> genetic mouse model in which thymocyte differentiation is blocked at the DN3a stage because of a non-functional pre-TCR/TCR (**S1 Fig. and S4A Fig.**). We observed that pre-TCR signalling did not modify the frequency of *SCL*-*LMO1*-induced pre-LSCs nor the genetic collaboration between *Notch1* and *SCL*-*LMO1* in thymocyte reprogramming (**Fig. 2C**). Moreover, the transplantation of pre-leukemic *Cd3ε*<sup>-/-</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes resulted in thymic reconstitution in primary, secondary and tertiary recipient mice (**S4B Fig., left panel**), associated with DN3 cell expansion over serial transplantations (**S4B Fig., right panel**), as observed with *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes (**Fig. 1C**).

We therefore took advantage of *Cd3ε*<sup>-/-</sup> mice to specifically assess the effects of the *Notch1* transgene. We transplanted *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes in competition with *Notch1*<sup>tg</sup> *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes. The formers were marked with GFP to distinguish between the two cell types. Strikingly, the hyperactive *Notch1* allele conferred a marked competitive advantage to *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic thymocytes when transplanted at equal concentrations both at the limiting ( $1 \times 10^3$ ) and higher ( $1 \times 10^6$ ) cell doses (**Fig. 2D and S4C Fig.**). *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup>*Gfp*<sup>tg</sup> thymocytes became competitive only when transplanted at 20-fold excess. These results indicate that oncogenic *Notch1* confers a competitive advantage to *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-LSCs.

December 2014 | Volume 10 | Issue 12 | e1004768





**Fig. 2. Notch1 collaborates with SCL-LMO1 to increase the pool of pre-LSCs and their competitiveness independently of a functional pre-TCR.** (A) The engraftment of *SCL-LMO1* DN3 thymocytes is abrogated by  $\gamma$ -secretase inhibitor (GSI) treatment prior to transplantation. DN3 thymocytes were purified from pre-leukemic *SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice and co-cultured on OP9-DL1 stromal cells in the presence or absence (vehicle) of 2.5  $\mu$ M DAPT (GSI) for 4 days. The total numbers of viable cells recovered per culture are shown (right panel). Following drug treatment, equal numbers of viable cells were transplanted ( $5 \times 10^4$  per mouse,  $n=5$ ). Engrafted mice: number of positive mice showing thymic reconstitution per group. (B) A hyperactive *Notch1* allele is insufficient to induce aberrant self-renewal in thymocytes but significantly enhances the engraftment of *SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes. Total thymocytes ( $1.5 \times 10^7$ ) from 1-week-old mice of the indicated genotype were transplanted; recipient mice were analyzed for thymic engraftment 3 weeks later. (C) Oncogenic *Notch1* increases the frequencies of *SCL-LMO1* pre-LSCs independently of a functional pre-TCR. Purified DN3 thymocytes from *SCL<sup>tg</sup>LMO1<sup>tg</sup>* and *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice with (*Cd3ε<sup>+/+</sup>*) or without (*Cd3ε<sup>-/-</sup>*) a functional pre-TCR were transplanted in limiting dilution assays (upper panel). Mice were scored positive when T-cell lineage reconstitution was more than 1%; pre-LSC frequencies and confidence intervals (lower panel) were calculated by applying Poisson statistics using the Limiting Dilution Analysis software (StemCell Technologies). (D) *Cd3ε<sup>-/-</sup>Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* pre-leukemic thymocytes outcompete *Cd3ε<sup>-/-</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes. Reconstitution by *Cd3ε<sup>-/-</sup>Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* (CD45.2<sup>+</sup> GFP<sup>+</sup>, closed circles) and *GFP<sup>tg</sup>Cd3ε<sup>-/-</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* (CD45.2<sup>+</sup> GFP<sup>+</sup>, open circles) thymocytes transplanted with the indicated cell numbers at 1:1 or 1:20 ratio. (E) *Notch1* expands the cellular targets of *SCL-LMO1* to DN1-4 and ISP8 cells. Pre-leukemic thymocyte subsets (DN1-4, ISP8 and DP) were purified from *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice and transplanted at  $5 \times 10^4$  cells per recipient mouse. The absolute numbers of donor-derived DN1-4 and ISP8 cells was calculated for each transplantation. doi:10.1371/journal.pgen.1004768.g002

### Constitutive *Notch1* activation expands the pool of *SCL-LMO1*-induced pre-LSCs to all DN-ISP8 populations

In addition, the capacity of *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes to engraft was no longer confined to DN3 but was found in all DN subsets (DN1-DN4) and immature single-positive CD8 (ISP8) cells but not in DP thymocytes (S4D Fig.). Strikingly, these purified DN-ISP8 thymocytes preferentially gave rise to the same populations in transplantation, indicative of self-renewal activity (Fig. 2E). Therefore, elevating *Notch1* activity was sufficient to convert all immature thymocytes (DN1 to ISP8) into cellular

targets of *SCL-LMO1* reprogramming activity. This expansion of cellular targets concurs with the limiting dilution assay indicating that *Notch1* increased the frequency of pre-LSCs.

We conclude that NOTCH1 levels determine the expressivity of *SCL-LMO1* in thymocyte reprogramming.

### The *Notch1-Hes1/Myc* pathway as an enhancer of *SCL/LMO1* self-renewal activity

Our findings indicate that *SCL-LMO1* self-renewal activity is confined to the DN3 stage (Fig. 1D), is GSI-responsive and is

sensitive to NOTCH1 levels (**Fig. 2A–B**). Interestingly, DN3 thymocytes are normally more sensitive to decreased *Notch1* gene dosage compared to earlier thymocyte progenitors [67]. We therefore capitalized on the comprehensive gene expression data from the Immunological genome project (Immgen) together with NOTCH1 ChIP-Seq data [68] and HSC self-renewal resources to inform about candidate genes in pre-LSC self-renewal. First, we investigated the upregulation pattern of NOTCH1-bound genes that are GSI-responsive during early thymocyte differentiation. Considering genes that increased by more than 1.3-fold at each transitional stage, the analysis revealed that the percentage of up-regulated NOTCH1-bound genes steadily increased from the ETP to the DN3a stage and decreased thereafter (**Fig. 3A and S2 Table**) as expected (reviewed in [69]). The general trend was also observed for the total transcriptome but the magnitude of the effect was stronger for the NOTCH1-bound genes (**Fig. 3A**). Furthermore, NOTCH1-bound genes sharply decreased at the DP stage when the total transcriptome increased. Finally, DN3 cells in WT and *SCL-LMO1* mice exhibit the highest levels of *Notch1* and *Notch3* genes and of the NOTCH reporter activity in Transgenic Notch Reporter (*TNR<sup>tg</sup>*) mice (**S5A–B Fig.**) as reported [23]. Therefore, NOTCH activity was highest in DN3 thymocytes, coinciding with the self-renewal activity of *SCL-LMO1*. *MYC* has been implicated downstream of *NOTCH1* in T-ALL [27]. Interestingly, we found that the increase in *MYC* target genes coincided with that of NOTCH1 and peaked at the DN2-DN3a transition (**Fig. 3A**).

Candidate genes operating with *SCL-LMO1* at the DN3 stage should also be GSI-responsive, as engraftment by *SCL-LMO1* DN3 thymocytes was DAPT-sensitive. These genes should operate prior to pre-TCR signalling, i.e. at the DN3a stage, since *SCL-LMO1*-induced self-renewal activity was fully efficient in *Cd3ε*-deficient DN3 thymocytes (**Fig. 2C and S4B Fig.**). Based on the list of GSI-responsive NOTCH1-bound genes published by Wang et al [68], 25 were found to increase at the DN2 to DN3a transition (**S2 Table**). We next intersected this short list with HSC self-renewal resources [70,71] and found 3 genes *Hes1*, *Myc* and *Bcl6* (**Fig. 3B**). We ruled out *Bcl6* because of high expression in DP cells that are resistant to cellular reprogramming while both *Myc* and *Hes1* decreased at this stage (**Fig. 3C**). We noticed that *Notch1* target genes correlate well with *Notch1* mRNA levels during thymocyte differentiation, except *Myc*. Despite this, the increase in *MYC*-bound genes at the DN2-DN3a transition correlates with that of NOTCH1-bound genes (**Fig. 3A**). These observations suggest *MYC* activity is subject to additional levels of regulation. *Myc* is a well known target of NOTCH1 in T-ALL [27,72]. Moreover, *Hes1* overexpression expanded HSCs in culture [70,73] whereas *Hes1* inactivation decreased LSCs in *Notch1*-induced T-ALL [24]. We therefore determined whether *Hes1* or *Myc* may be important for this new activity of *Notch1* at enhancing *SCL-LMO1* reprogramming activity.

To determine whether *Hes1* or *Myc* can substitute for *Notch1* as an enhancer of *SCL-LMO1*, we overexpressed these genes in HSCs from *SCL-LMO1* transgenic mice using the MSCV retroviral vector (**Fig. 3D**). Both *Hes1* and *Myc* caused an expansion of the DN3 population in transplanted mice, which was twenty to forty fold higher than that observed with the control vector (GFP) (**Fig. 3E**). Furthermore, all DN populations were expanded by *Myc* whereas the activity of *Hes1* was more specific to the DN3 population (**Fig. 3E and S6A Fig.**). Thymocytes overexpressing *Hes1* or *Myc* were recovered and transplanted into secondary mice at the limiting dose of ~1 CRU per mouse. Consistent with this limiting dose, the proportion of engrafted mice remained at 30% in the *Gfp* and *Hes1* groups (**Fig. 3F**),


suggesting that the frequency of pre-LSC was not modified by *Hes1*. Nonetheless, the total number of DN3 thymocytes recovered from these mice were modestly higher with *Hes1*. In contrast, *Myc* overexpression expanded the population of DN3 and 5 of 6 mice were reconstituted, indicative of increased pre-LSC frequency (**Fig. 3F**). Therefore, *Myc* expanded DN3 thymocytes and increased their self-renewal activities, thus recapitulating the activity of the *Notch1* transgene. In comparison, *Hes1* activity was mostly in DN3 expansion. Accordingly, thymocytes from *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice in which *Hes1* levels were decreased by a *Hes1*-directed shRNA (**S6B Fig., upper panel**) exhibited two-fold decreased regenerative capacities compared to control cells expressing the empty vector (**S6B Fig., lower panel**). Moreover, the self-renewing DN and ISP8 populations were similarly decreased while DP cells that lacked self-renewal activity were unaffected (**S6B Fig., lower panel**). Therefore, *Hes1* is required downstream of *Notch1* as an expansion factor, whereas *Myc* controls both self-renewal activity and cell expansion.

In summary, our results indicate that *Notch1* signal controls both *Hes1* and *Myc* and determines the capacity of DN3 thymocytes to be reprogrammed by *SCL-LMO1*.

### *SCL-LMO1* upregulated a stem cell gene signature in DN3 thymocytes


To identify candidate genes that confer self-renewal capability to pre-leukemic DN3 thymocytes, we made use of the *Cd3ε*-deficient mouse model in which oncogene-induced self-renewal activity was unaltered (**Fig. 4A**). We compared gene expression profiles of thymocytes from *SCL-LMO1* transgenic and age-matched non transgenic *Cd3ε<sup>-/-</sup>* mice, taken three weeks after birth. At this time point, the transcriptome analysis identified only 53 up-regulated and 33 down-regulated genes in *SCL-LMO1* expressing thymocytes (**S3 Table**), indicating that the gene expression programs in the two cell types were comparable. We compared this list of differentially expressed genes with the genome binding profiles of *SCL* and *LMO2* in several hematopoietic cell lines identified from a compendium of ChIP-seq datasets [74]. Within the down-regulated genes, only three had *SCL* peaks (*Cdc6*, *Cdkn1a* and *Slc4a1*) and none are presumed *LMO2* target. In contrast, 9 of the up-regulated genes are presumed direct *SCL* and *LMO2* targets (**S7A Fig. and S3 Table**). These observations concur with the view that *SCL* together with *LMO2* preferentially enhances transcription. We overlapped the *SCL-LMO1* up-regulated gene set with a compendium of molecular signatures (<http://discovery.hsci.harvard.edu/>). We found a subset of genes that are frequent in stem cell and cancer signatures (**S7B Fig. and S4 Table**), that includes *Hhex*, *Nfe2* and *Lyl1*. In particular, *Lyl1* is associated with HSC and cancer cell signature (**S7B Fig.**) and controls HSC survival [34] (**S7B Fig.**; [www.bonemarrowhsc.com](http://www.bonemarrowhsc.com)).

Next, we applied gene set enrichment analysis (GSEA) to uncover transcription factor signatures enriched in *SCL-LMO1* thymocytes, using a compendium of 55 ChIP-seq datasets representing 31 hematopoietic transcription factors from the HemoChIP project and others (see Materials and Methods). Surprisingly, the *LYL1* signature was the most up-regulated in *SCL-LMO1*-expressing DN3 thymocytes (**Fig. 4B**). Significantly, GSEA analysis also detected an up-regulated signature of *SCL* transcriptional partners, *GATA2*, *LMO2*, *LDB1*, *ETO2* and *SCL*, together with *LYL1* and *RUNX1*-bound genes [75]. On the other hand, NOTCH1 signature was not significantly enriched in this gene set, concurring with the view that *SCL-LMO1* and *Notch1* operate in parallel pathways. Furthermore, all *LYL1*-bound genes are comprised within the *SCL-LMO1*-bound gene



**Fig. 3. Functional importance of *Hes1* and *c-Myc* downstream of *Notch1* in thymocyte reprogramming induced by *SCL*-*LMO1*.** (A) Expression of GSI-responsive NOTCH1 target genes during thymocyte differentiation. Global gene expression data of thymocyte subpopulations were obtained from the Immunological Genome Project (<http://www.immgen.org/>). The percentage of GSI-responsive NOTCH1 target genes [68] or MYC target genes [120] that are up-regulated at each transitional stage during thymocyte differentiation (>1.3-fold change) are shown. (B) Filtering of GSI-responsive NOTCH1 target genes that increase at the DN2 to DN3a transition and are present in HSC self-renewal resources ([www.bioinfo.irc.ca/self-renewal/Main](http://www.bioinfo.irc.ca/self-renewal/Main) and [www.bonemarrowhsc.com](http://www.bonemarrowhsc.com)). (C) Gene expression profiles of *Notch1* and their target genes (*Notch3*, *Hes1*, *Il7r*, *Myc* and *Bcl6*) during thymocyte differentiation were collected from the Immunological Genome Project and represented as a heat map. (D) Schematic strategy to study the role of *Hes1* and *c-Myc* in self-renewal activity induced by *SCL*-*LMO1*. Lineage negative (LIN<sup>-</sup>) cells from *SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice (CD45.2<sup>+</sup>) were transduced with either MSCV-*Hes1* and MSCV-*Myc* retroviral vectors or with control MSCV-*GFP*. Equal number ( $5 \times 10^4$  cells) of purified GFP<sup>+</sup>LIN<sup>-</sup> cells were then transplanted in primary mice (CD45.2<sup>+</sup>). Donor-derived GFP<sup>+</sup>CD45.2<sup>+</sup> thymocytes were transplanted at the limiting dose of ~1 CRU ( $10^5$  cells) per mouse into secondary recipients. (E) Immunophenotype of donor-derived GFP<sup>+</sup>CD45.2<sup>+</sup> thymocytes in primary mice was analyzed by FACS (left panel) and the absolute number of DN3 cells was calculated (right panel). (F) The fold expansion of donor-derived GFP<sup>+</sup>CD45.2<sup>+</sup> DN3 thymocytes was calculated in secondary mice. doi:10.1371/journal.pgen.1004768.g003





**Fig. 4. *Ly1* coordinates a self-renewal network downstream of SCL-LMO1.** (A) Analysis of SCL-LMO1-upregulated genes in *Cd3e*<sup>-/-</sup> thymocytes. Gene signatures were analysed using the Stem Cell Discovery Engine tool as described in Experimental procedures, and signatures deemed enriched in SCL-LMO1 up-regulated genes (adjusted p-val <0.05) were classified into broad categories. The heatmap depicts the frequency of association to each gene by signature categories (stem cells, cancer, and other). (B) GSEA analysis of hematopoietic transcription factor signatures in SCL-LMO1 thymocytes. The lists of genes bound by 31 hematopoietic transcription factors within 2 kb of their proximal promoters were extracted from a compendium of ChIP-seq experiments (see Materials and Methods). The top 7 transcription factors are illustrated (FDR, false discovery rate, ranging from 0.01–0.32). In comparison, NOTCH1-bound genes were not up- or down-regulated by SCL-LMO1. (C) Hierarchical organisation of the self-renewal network controlled by SCL-LMO1. Integration of published ChIP-seq data [74] with up-regulated genes in DN3 pre-leukemic thymocytes identified common targets of SCL, LMO2 and LYL1 (highlighted in yellow). Incoming edges represent the binding of regulators at the proximal promoters of target genes (peaks within 2kb of the transcription initiation sites). (D) SCL and LMO1 occupy *Ly1* regulatory sequences. Chromatin extracts from the AD10.1 DN cell line expressing SCL (+SCL) or not (-SCL) were immunoprecipitated with the indicated antibodies. *Ly1* regulatory sequences were amplified by q-PCR. Data are expressed as fold enrichment over IgG controls. (E) *Ly1* gene expression is induced by SCL-LMO1 but is not modified by *Notch1* in DN3 thymocytes. mRNA levels in purified DN3 thymocytes from the indicated transgenic mice were determined by qRT-PCR and normalized to  $\beta$ -Actin (Mean  $\pm$  SD, n=3). doi:10.1371/journal.pgen.1004768.g004

set (S7A Fig., right panel). Overall, our transcriptome analysis predicted a hierarchy downstream of SCL-LMO1 in which *Ly1* could coordinate a *Notch1*-independent self-renewal network (Fig. 4C).

By ChIP analysis, we found that SCL occupancy of the *Ly1* locus in SCL-expressing DN cells (+ SCL) induced a 2- to 4-fold

higher LMO1 binding to the *Ly1* promoter compared to control cells (-SCL) (Fig. 4D). Finally, we observed by qRT-PCR that *Ly1* expression was significantly up-regulated by SCL-LMO1 (Fig. 4E), concurring with our microarray results. In contrast, the *Notch1* oncogene did not modify *Ly1* expression in DN3 thymocytes expressing or not SCL-LMO1 (Fig. 4E).

We conclude that *SCL* and *LMO1* induce aberrant stem cell gene expression in DN3 thymocytes and reprogram these cells to acquire stem cell-like properties.

### Inhibition of E protein is insufficient for leukemogenesis

*SCL* activates or represses gene expression, depending on its protein partners (reviewed in [76]). Transcription activation critically depends on direct *SCL*-*LMO1* or -*LMO2* interaction to assemble a transcription complex on DNA [36,37]. This interaction is dispensable for transcription inhibition of E protein targets, which is directly attributed to *SCL* interaction with *E2A* or *HEB*.

In particular, GSEA analysis indicated that *E2A*-presumed targets were not enriched within the list of differentially expressed genes (**S8A Fig.**), suggesting that inhibition of *E2A* activity by *SCL*-*LMO1* in DN3 thymocytes was not a major perturbation at the molecular level. We designed the *SCLm13* that is specifically defective in *LMO1/2* binding while heterodimerization with *E2A*/*HEB* was unaffected [37] (**S8B Fig.**). Compared to wild type *SCL*, *SCLm13* failed to activate the transcription of *Lyl1* in transient assays whereas inhibition of E protein activity remained intact (**S8C Fig.**). We previously identified *Ptcr*a as a direct target of *HEB*/*E2A* that is inhibited by *SCL* [46]. We therefore stably introduced *SCL* and *SCLm13* in the DN cell line AD10 and found that both genes inhibited the expression of *Ptcr*a to the same extent, indicating that direct *SCL*-*LMO1/2* interaction was dispensable for inhibition of E proteins (**S8D Fig.**).

E proteins are major cell fate determinants in the thymus [77,78], leading to the current view that T-ALL induction by *SCL*-*LMO1/2* is due to E protein titration and inhibition [47]. To directly address the question whether the inhibition of *E2A* by *SCL*-*LMO1* was sufficient for leukemogenesis, we generated transgenic mice expressing wild type *SCL* or the *SCLm13* mutant at comparable levels (**Fig. 5A–B**). We observed that *SCLm13* fully retained its capacity to inhibit the expression of E protein target genes in DN3 thymocytes (**Fig. 5C**). Significantly, while *SCLm13* still inhibited E proteins (**S8D Fig.**), there was a striking difference between the survival curves of *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *SCLm13*<sup>tg</sup>*LMO1*<sup>tg</sup> transgenic lines (**Fig. 5D**). *LMO1*<sup>tg</sup> mice develop T-ALL with 20% penetrance and delayed onset at 400 days, as reported [39]. In contrast, the disease was fully penetrant in *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice, with an accelerated onset of 170 days [17,40]. In *SCLm13*<sup>tg</sup>*LMO1*<sup>tg</sup> mice however, leukemia onset was delayed to 380 days and the penetrance reduced to 65% (**Fig. 5D**), underscoring the importance of *SCL*-*LMO1* interaction in leukemogenesis. To further address the question whether the genetic collaboration between *SCL* and *LMO1* in leukemogenesis was due to inhibition of E proteins, we generated *E2a*<sup>+/-</sup>*LMO1*<sup>tg</sup> mice. Loss of one *E2a* allele significantly decreased expression levels of *E2A* target genes in DN thymocytes (**S8E Fig.**) but did not mirror the collaboration of the *SCL* transgene with *LMO1* to induce T-ALL. Together, our results indicate that inhibition of *E2A* is insufficient for leukemogenesis and that direct *SCL*-*LMO1* interaction is an important determinant of leukemia onset and disease penetrance.

### Transcription activation by *SCL*-*LMO1* is required for thymocyte reprogramming

We next addressed the question whether direct *SCL*-*LMO1* interaction is required for self-renewal activity in DN3 thymocytes. The *m13* mutation severely impaired the activation of self-renewal genes including *Lyl1* (**Fig. 5E**) and drastically decreased the capacity of total thymocytes (**Fig. 5F**) or purified DN3 thymocytes (**S9A Fig.**) to reconstitute the thymus of transplanted hosts.

Thymic engraftment of *SCLm13*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes were reproducibly decreased to levels observed with *LMO1*<sup>tg</sup> only. Nonetheless, *SCLm13* retained the same capacity as *SCL* to block the DN to DP transition compared to *LMO1* alone (**Fig. 5G and S9B Fig.**), a transition stage controlled by *E2a* and *Heb* gene dosage [79,80]. Together, our results indicate that inhibition of E protein and thymocyte differentiation blockade are distinct from the acquisition of self-renewal activity, which requires direct *SCL*-*LMO1* interaction and transcription activation of a self-renewal program.

### *Lyl1* can substitute for *SCL* to collaborate with *LMO1* and reprogram thymocytes

Network analysis point to the importance of *Lyl1* downstream of *SCL*-*LMO2* (**Fig. 4C**), consistent with published results [61]. Yet, ectopic expression of *Lyl1* on its own did not recapitulate *LMO2*-induced aberrant self-renewal in thymocytes [9]. We reasoned that *LYL1* activity most likely requires interaction with *LMO1/2* for the following reasons: (i) the *SCL* interaction interface with *LMO1/2* is conserved in *LYL1* [36]; (ii) *LYL1* is in complex with *SCL* and *LMO2* [81]; (iii) *LYL1* binding to DNA often overlaps with *SCL* and *LMO2* binding [75]; and (iv) *Lyl1* is redundant with *Scf* in controlling HSC self-renewal [34]. We therefore generated *LYL1*<sup>tg</sup>*LMO1*<sup>tg</sup> mice to address the question whether *LYL1* enhances *LMO1* self-renewal activity. *LYL1* enhanced by 3-fold the activity of *LMO1* on thymocyte engraftment (compare **Fig. 6A, left panel** and **Fig. 5F**), whereas *LYL1* alone did not reprogram thymocytes as expected. Similar to *SCL*-*LMO1*, *LYL1*-*LMO1* expanded DN3 cells only after transplantation (**Fig. 6A, right panel** and **S10 Fig.**) and this expansion was in the same order of magnitude compared to the inactive *SCLm13*-*LMO1* (**Fig. 6B**). The virtual convergence of *SCL*-*LMO2* and *LYL1*-*LMO2* target genes (**Fig. 4C**) may explain the capacity of *LYL1*-*LMO1* to mimic *SCL*-*LMO1* in DN3 thymocytes (**Fig. 6A–B**).

By RNA-Seq of 12 T-ALL patient samples, we found that *LYL1* and *HHEX* mRNA levels are highly correlated with *LMO2* levels ( $r=0.8$ , **Fig. 6C**), concurring with the view that *LYL1* and *HHEX* are downstream targets of *LMO2* in T-ALL.


Interestingly, *LYL1* expression in the absence of *TAL1* was found in 4 of 12 samples but *TAL1* expression was never found in the absence of *LYL1* (**Fig. 6C**). These observations concur with the view that *TAL1* is upstream of *LYL1* (**Fig. 4C–E**) and with the essential role of *Lyl1* in pre-thymic progenitors as well as in ETP-DN2 [82]. Moreover, the absence of correlation between *TAL1* and *LMO2* mRNA levels are consistent with the observations that *LYL1*, but not *TAL1*, is essential for *LMO2*-induced T-ALL [61].

We observed higher *LYL1*, *LMO2*, *HHEX* and *MEF2C* levels in ETP and pro-T ALL in adult (**Fig. 6C**) and pediatric (**S11 Fig.** [38]) T-ALL, consistent with this gene triad being direct targets of activation by *MEF2C* [83]. Nonetheless, *LYL1* and *LMO1/2* expression was detected in a majority of T-ALL samples independently of *MEF2C* or of phenotypic classification and included *TLX1/3*- and *HOXA9*-expressing leukemias (**Fig. 6C and S11 Fig.**). These observations suggest that the molecular pathways controlling self-renewal described here is not limited to T-ALL samples harboring *TAL1* or *LMO1/2* translocations but may be relevant to other oncogenic subtypes of T-ALL.

## Discussion

### Self-renewal as an initiating event in leukemia


Self-renewal is a mandatory trait of cancer stem cells as drivers of clonal expansion and evolution through layers of selective



**Fig. 5. Transcription activation driven by SCL-LMO1 interaction is critical for thymocyte reprogramming and T-ALL induction.** (A) Generation of transgenic mice expressing the LMO1-binding defective mutant SCLm13. The sequence coding for wild type human SCL or human SCLm13 HLH domain mutant [37] were cloned into the VA hCD2 cassette to generate transgenic mice. Shown are amino acids of the HLH region of SCL or SCLm13. (B) Immunofluorescence of human SCL (wt or m13) by flow cytometry. Thymocytes were stained with the monoclonal antibody against human SCL (BTL73). Control cells were stained with the second antibody only. (C) Expression of E protein target genes is inhibited both by SCL-LMO1 and SCLm13-LMO1 transgenes in DN3 thymocytes. mRNA levels in purified DN3 thymocytes from the indicated transgenic mice were determined by qRT-PCR and normalized to  $\beta$ -Actin (Mean  $\pm$  SD,  $n=3$ ). (D) Kaplan-Meier curves of the time to leukemia for LMO1<sup>tg</sup>, E2a<sup>+/-</sup>LMO1<sup>tg</sup>, SCL<sup>tg</sup>LMO1<sup>tg</sup> and SCLm13<sup>tg</sup>LMO1<sup>tg</sup> mice. (E) The interaction between SCL and LMO1 is required to activate the transcription of the self-renewal genes *Lyl1*, *Hhex* and *Nfe2* in DN3 thymocytes. mRNA levels in purified DN3 thymocytes from the indicated transgenic mice were determined by qRT-PCR and normalized to  $\beta$ -Actin (Mean  $\pm$  SD,  $n=3$ ). (F-G) SCL but not the LMO1-binding defective SCL-m13 mutant collaborates with LMO1 to induce abnormal thymic reconstitution potential to thymocytes. Pre-leukemic thymocytes ( $1.5 \times 10^7$  cells) from 3-week-old mice were transplanted. Recipient mice were analysed for thymic reconstitution (CD45.2<sup>+</sup>Thy1<sup>+</sup>) after 6 weeks (F) and the proportion of DP cells in engrafted CD45.2<sup>+</sup>Thy1<sup>+</sup> thymocytes was assessed by FACS (G). doi:10.1371/journal.pgen.1004768.g005

pressure [7]. This self-renewal activity is essential for long-term propagation. We now provide evidence that self-renewal is an initiating event triggered by the reactivation of stem cell genes in thymocytes (Fig. 7A), as exemplified by chromosomal translocations driving ectopic *SCL*, *LYL1* or *LMO1/2* expression in thymocytes. Our data indicate that *LYL1* coordinates a self-renewal network downstream of SCL-LMO1 to reprogram thymocytes with a finite life span into self-renewing pre-LSCs. Importantly, these self-renewal genes require the high levels of

physiological NOTCH1 in DN3 thymocytes for expressivity. Their activities are therefore modulated by the thymic microenvironment. Furthermore, the *Notch1* oncogene is devoid of intrinsic self-renewal activity but dramatically enhances SCL-LMO1 activity by conferring a proliferative advantage to SCL-LMO1-primed pre-LSCs and by recruiting all immature thymocytes into division to expand the pool of pre-LSCs (Fig. 7B). Consequently, the hyperactive *NOTCH1* allele acts as a strong enhancer of SCL-LMO1 by conferring additional fitness traits to



**Fig. 6. *LYL1* and *LMO1/2* are co-expressed in human T-ALL and collaborate to reprogram thymocytes.** (A) *LYL1* collaborates with *LMO1* to induce abnormal thymic reconstitution potential to thymocytes.  $1.5 \times 10^7$  thymocytes from the indicated mice were transplanted and thymic engraftment was analyzed after 6 weeks (left panel). Representative FACS profile of engrafted *LYL1*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes (right panel). (B) *LYL1*-*LMO1*-induced DN3 expansion was comparable to *SCL*-*LMO1*-induced expansion after transplantation, as illustrated by the box plots (with the median and extreme values of each distribution, cohorts of n mice). (C) *LMO2* expression levels correlate with *LYL1* levels in T-ALL patient samples. Illustrated are the RPKM values for the indicated human gene. Note the high correlation coefficient between *LMO2* and *LYL1* and the absence of correlation with *TLX1/3*.


doi:10.1371/journal.pgen.1004768.g006

*SCL*-*LMO*-initiated pre-LSCs, and allows for escape from environmental signals.

#### Transcription activation by *SCL*-*LMO1*: reprogramming DN3 thymocytes into self-renewing pre-LSCs

*LMO2* interaction with *SCL* has several consequences. First, interaction with *SCL* protects *LMO1/2* from proteasomal degradation [37]. Second, *SCL* brings *LMO2* to DNA, with two possible outputs: transcription activation or transcription inhibition. E proteins are major drivers of thymocyte development by activating gene expression programs that control cell survival, cell cycle and T-cell differentiation. In particular, *SCL*-*LMO1* inhibit

E protein activity and thymocyte differentiation [46,47], leading to the current view that *SCL*-*LMO1/2* induced T-ALL is due to E protein inhibition [47]. We bring several lines of evidence to indicate that the inhibition of E proteins is not the major cause of T-ALL. First, within the differentially expressed gene set in *SCL*-*LMO1* DN3 thymocytes, we found a significant enrichment for binding by all *SCL* transcriptional partners, whereas *E2A* binding was not enriched. Second, removal of one *E2a* allele did not collaborate with *LMO1* to induce T-ALL even though *E2a* was haploinsufficient for target gene expression. Third, we show that inhibition of E protein activity by the *SCLm13* mutant did not enhance *LMO1* self-renewal activity, resulting a dramatically



**Fig. 7. Model of the collaboration between the *SCL*, *LMO1* and *Notch1* oncogenes.** (A) *SCL* and *LMO1* interact to upregulate *Lyl1* gene expression and create a feed forward loop that activates self-renewal in DN3 thymocytes. DN3 cells are prone to *SCL-LMO1* self-renewal activity due to higher physiological NOTCH levels. (B) The *Notch1* oncogene drastically enhances *SCL-LMO1*-induced self-renewal activity to expand the pool of target cells to DN1-4 and ISP8 in a parallel pathway via *Hes1* and *c-Myc*. *SCL-LMO1* initiated cells (A) subsequently acquire gain of function *Notch1* mutations (B), causing target cell expansion and escape from thymic environmental control. doi:10.1371/journal.pgen.1004768.g007

decreased leukemogenic activity compared to wild type *SCL*, as assessed by decreased penetrance and increased latency. The modest enhancement of *LMO1* in T-ALL induction by *SCLm13* remains compatible with a tumor suppressor function for E proteins [47]. Therefore, the interaction of *LMO1* with *SCL*, which is required to assemble a transcriptionally active complex on DNA [37], is an important determinant of T-ALL development due to the reactivation of stem cell genes in DN3a thymocytes, during the pre-leukemic stage. By network analysis of the *SCL-LMO1* transcriptome in DN3a thymocytes, we identified a hierarchy downstream of *SCL-LMO1* which is controlled by *Lyl1*. Previous work indicated that *Lyl1* is critical for the oncogenic functions of *LMO2*, consistent with a non-redundant function for *Lyl1* in lymphoid progenitors and ETP [82]. This finding not mirrored by ectopic *Lyl1* expression in the thymus [9] whereas *Hhex* deficiency [84] is mirrored by *Hhex* overexpression [9]. Considering that *LYL1* and *LMO2* chromosomal rearrangements were found simultaneously in a rare case of human T-ALL [85], we now report that *LYL1* collaborates with *LMO1* to reprogram DN3 thymocytes.

In summary, we provide genetic evidence that transcription activation by *SCL* and *LMO1* is a major determinant of self-renewal in pre-LSCs and of the aggressiveness of T-ALL.

#### *Notch1* as a strong enhancer of *SCL-LMO1* that expands the pool of pre-LSCs

NOTCH signaling is essential for T-cell commitment and specification. In particular, NOTCH1 cooperates with the pre-TCR to control cell survival and proliferation at the DN to DP transition [14], at a critical checkpoint in the thymus. We previously showed that pre-TCR activity at the DN3 stage is required for the acquisition of *Notch1* mutations in *SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes [17]. Once mutated, these hyperactive *Notch1* alleles are sufficient to drive progression to T-ALL in concert with

*SCL-LMO1*. Therefore, the pre-TCR is a strong determinant of leukemia onset and of disease penetrance. Strikingly, we show here that the initiating event of reprogramming DN3 thymocytes into self-renewing pre-LSCs by *SCL-LMO1* is independent of the pre-TCR but requires NOTCH1 signal. Taken together, our observations indicate that the pre-TCR is a collaborating event in disease progression but dispensable for the initial transition from DN3 cells to pre-LSCs. In contrast, we show that high levels of physiologic Notch signals in DN3 cells were required for *SCL-LMO1* reprogramming activity.

Functional studies of the *NOTCH1* oncogene at time of overt leukemia in both human [21,22] and murine LSCs [23,86,87] showed that NOTCH1 controls leukemia initiating cell activity. In contrast, the role NOTCH1 in HSC self-renewal was controversial [30,88,89]. Using the mouse model as a unique opportunity to specifically understand initiating events in T-ALL, we unexpectedly found that a hyperactive *NOTCH1* allele is devoid of intrinsic reprogramming activity in thymocytes, suggesting that weaker leukemia-associated *Notch1* alleles [30] also lack this activity, similar to *Notch3* [9]. Instead, high levels of NOTCH1 activity sensitize target cells to the reprogramming activity of *SCL* and *LMO1*. Indeed, supraphysiologic NOTCH signaling was required past the DN3 stage, when physiologic NOTCH activity fell sharply. Therefore, our work provides a distinct conceptual framework to grasp the significance of the frequent co-occurrence of *NOTCH1* gain of function mutations with major classes of oncogenic transcription factors in T-ALL.

Multiple genetic interactions have been described for *Notch1* [26,27,90] (reviewed in [91]). Similar to *Notch1*, *Hes1* also drives T-cell development and inhibits alternate fates [92]. Interestingly, the conditional invalidation of *Hes1* in adult hematopoietic cells led to T-cell defects and disrupted T-ALL maintenance [24]. Whether *Hes1* contributes to oncogenic reprogramming of thymocytes at the initiation of the disease remained to be

addressed. Here, we show that the hyperactive *Notch1* allele upregulates *Hes1* by 4-fold in DN3 thymocytes, which was insufficient for thymocyte self-renewal *in vivo* and required co-expression of the *SCL-LMO1* oncogenes.

*Myc* is required for the correct balance between self-renewal and differentiation of normal HSCs. Indeed, enforced *Myc* expression leads to HSC exhaustion whereas *Myc* deficiency results in increased HSC pool and self-renewal [93–95]. Our analysis of the Immgen data set indicates that MYC target genes but not *Myc* mRNA levels correlate with NOTCH1 activity during normal differentiation. This indicates additional levels of regulation; in particular MYC proteins are regulated by the ubiquitin ligase FBW7 in HSCs [96], which is frequently mutated in T-ALL patients [97]. These observations point to the critical importance of regulating MYC levels in thymocytes. *MYC* is a well-documented target of *NOTCH1* in leukemogenesis [27]. Furthermore, *Myc* promotes fibroblast reprogramming into induced pluripotent stem cells [98]. We now show that ectopic *Myc* expression in thymocytes recapitulates the activity of the *Notch1* transgene to enhance thymocyte reprogramming by *SCL-LMO1*. Our observations on the role of *Notch1-Myc* as an enhancer of *SCL-LMO1* shed light on the pathway through which the BET-bromodomain inhibitors (JQ1) that inhibited *Myc* could decrease the growth of primary leukemic cells, i.e. most likely due to interference with the NOTCH1 pathway [87,99,100]. Finally, our observations on the primordial role of *Myc* over *Hes1* in substituting for NOTCH1 signals is consistent with the model of feed-forward-loop activated by NOTCH1 and MYC that promotes leukemic cell growth [29].

Therefore, our work clarifies the important role of *Notch1-Hes1/Myc* in the thymus as enhancers of self-renewal, but not as oncogenes with reprogramming activity. The *Scl* and *Lmo2* genes [46] are silenced in DN3 thymocytes by a repressive histone mark [13]. We therefore surmised that chromosomal translocations or retroviral integration upstream of the *LMO2* locus observed in pediatric T-ALL overcome these repressive marks to cause ectopic expression of oncogenes such as *LYL1*, *SCL* and *LMO2* which, in the context of DN3 thymocytes, collaborate with *NOTCH1-HES1/MYC* to confer aberrant self-renewal to these cells. We therefore propose a model in which *SCL-LMO1-Lyl1* and *Notch1-Hes1* are complementary in thymocyte reprogramming (Fig. 7B).

### Oncogenic reprogramming sets a pre-leukemic state by enabling self-renewal

Phenotypic plasticity or lineage infidelity is often observed in cancer [101]. A recent report indicates that phenotypic plasticity predisposes reprogrammed fibroblasts to express stem cell characteristics and to induce tumors in nude mice [102]. In contrast, we show here that pre-leukemic stem cells conserve their DN3 phenotype through three rounds of transplantation and that the acquisition of self-renewal as an essential stem cell characteristic can occur in the absence of phenotypic plasticity. Therefore, our data indicate that phenotype plasticity is not an essential premise for oncogenic reprogramming whereas self-renewal is a mandatory trait [7].

The cell of origin of T-ALL was inferred from the phenotype of the leukemic cells [38], or of LICs which was closer to the phenotype of a T-cell progenitor [22,103]. Nonetheless, LICs have evolved through several selective constraints and acquired additional complexity and are defined as cells that produce an overt invasive leukemia. Here we define the cell of origin of T-ALL and the mechanisms by which oncogenes reprogram normal thymocytes. We bring evidence that the activation of a self-renewal program requires collaboration between several

genes and incoming environmental signals, which is likely to determine the nature of the cell of origin of leukemia. Thus, *SCL*, *LYL1* or *Notch1* are not endowed with intrinsic reprogramming activity. Both *SCL* and *LYL1* strongly enhanced *LMO1* self-renewal activity in DN3 thymocytes due to higher endogenous NOTCH1. Furthermore, the combination of three oncogenes, *Notch1*, *SCL* and *LMO1* had the strongest effect on self-renewal. Therefore, our data provide new mechanistic insights into the original two-hit model of cell transformation. Instead of each oncogene acting independently as a master switch in leukemia initiation, our work argues for the coincidence detection model in which biological outputs depend on the simultaneous occurrence of multiple signals within a network. Such cooperativity governs the process of self-renewal in pre-LSCs, which is an initiating event in T-ALL.

High *LYL1* and *LMO2* expression in T-ALL was previously associated with immature or ETP-ALL [38,83,104]. While *TAL1* expression in T-ALL was linked with a late cortical stage of T cell differentiation on the basis of cell surface markers [38] or whole transcriptome [104], we provide cellular and genetic evidence that the initiating events occur in earlier stages in which NOTCH1 signals are highest, i.e. at the DN2b to DN3a transition, and that the *Cd3ε* gene is dispensable. These observations prompted us to examine the transcriptome of human adult T-ALL (LeuceGene-IRIC) [105] and pediatric T-ALL [38]. This analysis also revealed that *LYL1* and *LMO2* were high in ETP and pro-T ALL but were detectable in almost all samples, suggesting that the molecular network defined in our study might operate in most T-ALL [106]. The importance of the *SCL-LMO1* interaction described here for pre-LSC self-renewal activity, combined with the molecular view of this interaction interface suggests that targeting *SCL-LMO1* interaction might represent a novel and promising therapeutic avenue. Such approach will be applicable to *LYL1-LMO2* since the residues interacting with *LMO2* are conserved between *SCL* and *LYL1*.

## Materials and Methods

### Mice and ethics statement

All animals were maintained in pathogen-free conditions according to institutional animal care and guidelines set by the Canadian Council on Animal Care. Our protocol entitled “T-cell acute lymphoblastic leukemia induced by the *SCL* oncogene” was approved by the Ethics Committee of experimentation on animals of the University of Montreal, CDEA (Comité de d’Oncologie de l’expérimentation sur les animaux).

Transgenic mice were previously described: *pSil-TSCL* (*SCL*<sup>tg</sup>) [40], *Lck-LMO1* (*LMO1*<sup>tg</sup>) and *Lck-Notch1C9* (*Notch1*<sup>tg</sup>) (NIAID/Taconic Repository Bethesda), *E2a*<sup>+/−</sup> [107], *Lck-LYL1* (*LYL1*<sup>tg</sup>) (International Mouse Strain Resource), *Transgenic Notch Reporter* (*TNR*<sup>tg</sup>) (Tg(Cp-EGFP)25Gaia, The Jackson Laboratory, Maine, United States) and *Cd3ε*<sup>−/−</sup> [108]. Mice cohorts were generated by cross-breeding. Their genotypes were verified by PCR. The gene encoding the short isoform (p22) of wild-type and m13 mutant [37] *SCL* protein was amplified by PCR using the following primers: 5′-GCGCGAATTCATGGAGATTACTGATGGT-3′ and 5′-TATACCCGGGTCACCGAGGGCCG-GCTCC-3′. These fragments were digested with *EcoRI* and *SmaI* and subcloned in *Cd2-VA* minigene construct (gift from Dr Dimitris Kiousis, National Institute for Medical Research, London, UK) [109,110]. DNA was microinjected into the pronucleus of C57BL6 mice by IRIC Transgenesis Core Facility, University of Montreal. Transgenic mice were backcrossed into the C57BL6 background for more than 10 generations.



### Transplantation assay

Pre-leukemic thymocytes from donor mice (CD45.2<sup>+</sup>) are transplanted intravenously into sub-lethally irradiated (600cGy) recipient mice (CD45.1<sup>+</sup>). Thymic chimerism in the T-lineage (Thy1.2<sup>+</sup>) was analysed by flow cytometry (FACS) and illustrated by the percentage of donor-derived cells (% CD45.2<sup>+</sup>) found in the recipient thymus.

### Limiting dilution assays

Pre-leukemic thymocytes from *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *Notch1*<sup>tg</sup> *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice were transplanted into sub-lethally (600 cGy) irradiated hosts (CD45.1<sup>+</sup>) at various cell doses (10<sup>7</sup>, 10<sup>6</sup>, 10<sup>5</sup>, 10<sup>4</sup>, 10<sup>3</sup>, and 10<sup>2</sup>) per recipient mouse (n = 7 mice for each dose). Mice were scored positive when T-cell lineage reconstitution was more than 1%. Pre-leukemic stem cell (pre-LSC) frequency (Range pre-LSC ± Confidence Interval) and Competitive Re-populating Unit (CRU) frequency for the indicated genotypes were calculated by applying Poisson statistics using the Limiting Dilution Analysis software (Stem Cell Technologies). The same strategy was used to compare the pre-LSC frequencies of DN3 *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *Cd3ε*<sup>-/-</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes. The mean activity of pre-leukemic stem cells (MAS) is calculated according to the Harrison formula [111,112]. MAS represent the pre-LSC potential of approximately 1 CRU: MAS = [RU]/[CRU] where RU represents the re-populating activity of pre-LSC and CRU was determined by limiting dilution analysis as above. RU was calculated as previously described [33]. Since the number of competitor cells corresponds to the number of cells in the thymus of sub-lethally irradiated recipient mice, the formula was applied as follows: RU = [number of donor-derived cells]/[number of competitor host cells in recipient mouse thymus].

### In vivo competitive assay

Pre-leukemic *Cd3ε*<sup>-/-</sup>*Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes (CD45.2<sup>+</sup> GFP<sup>+</sup>) from one-week-old mice were mixed with *Cd3ε*<sup>-/-</sup>*Gfp*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> competitor thymocytes (CD45.2<sup>+</sup> GFP<sup>+</sup>) in two ratios (1:1 and 1:20) at the indicated cell doses in Fig. 2D and S4C Fig. Mixed cells were then transplanted in irradiated hosts (CD45.1<sup>+</sup>). Thymic reconstitution by transplanted cells was assessed by FACS analysis 3 weeks post-transplantation.

### Immunostaining and FACS analysis

Single-cell suspensions were prepared from thymi of mice of the indicated ages and genotypes. Immunostaining was done as previously described [46]. All antibodies used for flow cytometry analysis were from Pharmingen (BD Biosciences, Mississauga, Ontario, Canada): CD44 (IM7), CD25 (PC61.5), CD4 (RM4-4), CD8 (53-6.7), Thy1.2 (30-H12) and CD24 (30-F1). Dead cells were excluded by propidium iodide staining. FACS, cell cycle and cell division analysis were performed on a LSRII cytometer (BD Biosciences) using DIVA (BD Biosciences) and ModFit LT (Verity Software House, Topsham, Maine, United States) software.

### Nuclear SCL labeling

For nuclear SCL labeling, thymocytes were fixed and permeabilized with Fixation/Permeabilization Solution Kit and washed 3 times with Perm/Wash buffer (BD Cytofix/Cytoperm, 554714; BD Biosciences, Mississauga, Ontario, Canada). The cells were then labeled with the monoclonal anti-human SCL BTL73 [113] at 1:10 dilution, washed extensively with PBS, followed by a goat anti-mouse antibody coupled to FITC. The antibody was a generous gift from Danièle Mathieu-Mahul (Institut de Génétique Moléculaire, Montpellier, France).

### Co-culture conditions

Pre-leukemic cells were purified by FACS from transgenic mice and co-cultured on (GFP-positive) OP9 and OP9-DL1 stromal cell lines, as described previously [66]. Briefly, pre-leukemic cells were co-cultured on OP9 and OP9-DL1 cells in reconstituting a-MEM medium (12561, Gibco, Life Technologies, Burlington, Ontario, Canada) supplemented with 10% FBS (12318, Gibco), HEPES 10 mM (15630-080, Gibco), sodium pyruvate 1 mM (11360-070, Gibco), b-mercaptoethanol 55 μM (21985-023, Gibco), glutamax 2 mM (15750-060, Gibco), penicillin/Streptomycin (15140-122, Gibco), 5 ng/mL FLT-3 Ligand (308-FK, R&D system) and 5 ng/mL IL-7 (407-ML, R&D system). Medium was half changed twice per week and the cells were counted and phenotyped by FACS after co-culture.

### T-cell activation assay

T-cell stimulation was assessed using anti-CD3/CD28 beads as previously described [114]. Briefly, engrafted *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic T cells (donor thymocytes) and host thymocytes were purified by FACS and co-cultured on a OP9-DL1 stromal cell line over 3 days with anti-CD3/CD28 beads (Dynabeads Mouse T-Activator CD3/CD28, 114.52D, Invitrogen, Life Technologies, Burlington, Ontario, Canada). The expression of the activation marker CD69 (H1.2F3, eBioscience, San Diego, California, United States) was then analyzed by flow cytometry at the surface of SP4 and SP8 cells. Host B cells purified from the spleen were used as a negative control.

### Cell cycle assay

DN3 thymocytes from WT, *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup>, *Notch1*<sup>tg</sup> and *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice were purified by FACS and co-cultured on OP9-DL1 stromal cell line during 3 days. Derived-thymocytes were immunostained with T cell markers and then fixed and permeabilized (Cytofix/Cytoperm Plus, BD Bioscience) during 30 minutes before the staining with the Ki67-FITC antibody. The DAPI was added at the end of the staining as a marker of DNA content. Cycle cycle analysis of DN3 thymocytes was finally analysed by FACS.

### Microarray analysis

RNAs collected from *Cd3ε*<sup>-/-</sup> and *Cd3ε*<sup>-/-</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes were amplified and hybridized onto Affymetrix Mouse Genome 430A 2.0 arrays (Ottawa Genome Centre, Ottawa, Ontario, Canada). Raw data pre-processing and differential expression analysis was carried out using Bioconductor packages in the R environment, according to the following pipeline: (i) probesets were summarized and normalized using the RMA procedure implemented in the Affy package [115]; (ii) absent/present probesets were detected using the MAS5 implementation of the Affy package, and probesets deemed absent in both conditions (*Cd3ε*<sup>-/-</sup> and *Cd3ε*<sup>-/-</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup>) were removed from downstream analysis; and (iii) detection of differentially expressed genes was carried out using the Rank Products package [116].

### Collection and analysis of ChIP-Seq datasets

We collected genome-wide chromatin occupancy data for 31 hematopoietic transcription factors (51 ChIP-seq experiments in total) from Wang et al [68] and the HemoChIP project [74]. NOTCH1-binding peaks in G4A2 and T6E murine cell lines were computed using the Galaxy tool, according to the following steps: (i) sequence reads were mapped to the mouse genome mm9 using Bowtie with default parameters (maximum 2 mismatches); and (ii) peak coordinates were determined by the MACS tool, using the

Pvalue cutoff  $<10^{-9}$ . Peak coordinates for the HemoChIP dataset mapped to the mouse genome mm9 were downloaded from [http://hscl.cimr.cam.ac.uk/ChIP-Seq\\_Compendium/ChIP-Seq\\_Compendium2.html](http://hscl.cimr.cam.ac.uk/ChIP-Seq_Compendium/ChIP-Seq_Compendium2.html). Finally, all peaks were associated to their closest transcription start sites in the mouse genome using PeakAnalyzer v.1.4 tool [117]. Gene lists bound by transcription factors used in downstream analyses (Figs. 4A, 5D, 6A) included only those genes containing at least one binding site for the given regulator within the proximal promoter (2 kb region around the transcription start site).

### RT-qPCR

Total RNAs were prepared from 50,000 purified cell population cells from 1-week-old mice using RNeasy extraction kit (Qiagen, Mississauga, Ontario, Canada). First strand cDNA syntheses were performed by reverse transcription as described [46]. Primer sequences are listed in S5 Table. Real-time quantitative PCR was done with SYBR Green Master Mix (Applied Biosystems, Foster City, California, United States) on Stratagene Mx3000 apparatus (Stratagene, La Jolla, California, United States).  $\Delta\Delta C_t$  values were calculated using *Ct* values from  *$\beta$ -actin* gene as reference.

### ChIP assays

The DN thymoma cell line AD10.1 [46] was cultured in IMDM (Invitrogen, Burlington, Ontario, Canada) containing 10% inactivated foetal calf serum (FSC) and 50  $\mu$ M  $\beta$ -mercaptoethanol. The parental cell line was retrovirally transduced with MSCV empty vector or MSCV-SCL-expressing vector, and stable transfectants were kept under neomycin selection (1 mg/mL). Chromatin immunoprecipitation were performed as described previously [118] using the following antibodies: anti-SCL mouse monoclonal antibodies BTL73 (generously provided by Dr. D. Mathieu-Mahul, Institut de Génétique Moléculaire, Montpellier, France), rabbit anti-LMO1 (Bethyl Laboratories, A300-314A; Cedarlane Laboratories, Burlington, Ontario, Canada), and anti-rabbit IgG (Sigma, St-Louis, Missouri, United States). Oligonucleotide sequences used for promoter amplification are shown in S5 Table.

### Gene transfer into bone marrow cells

Gene transfer into bone marrow cells from 1-week-old pre-leukemic *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice was performed essentially as previously described [119]. Bone marrow cells were depleted of lineage positive cells through immunomagnetic bead separation (LIN<sup>-</sup>) and plated in suspension culture in IMDM with 15% FCS, 100 ng/mL murine Steel Factor (SF), 10 ng/mL human IL-6, 100 ng/mL human IL-11 and 5 ng/mL murine IL-3, at a concentration of  $1 \times 10^6$  cells/mL. All cytokines were produced as COS cell supernatants and were calibrated against recombinant standards. For the over-expression of Hes1 and c-Myc, LIN<sup>-</sup> cells were overlaid on irradiated (1500 cGy) virus producing GP+E-86 cells containing the MSCV-GFP or -Hes1 or c-Myc in the presence of 0.8  $\mu$ g/mL of polybrene (Sigma Aldrich) for 48h. For the down-regulation of Hes1, LIN<sup>-</sup> cells were infected using lentiviral vectors containing either non-targeting shCTL or shHes1 (Sigma, TRCN0000028854; St. Louis, Missouri, United States) for 48 h. Following infection, cells were selected for 2 d with puromycin (1.5  $\mu$ g/mL) and transplanted into irradiated CD45.1 hosts.

### Transcriptome sequencing of T-ALL patient samples

11 T-ALL samples were collected by the Quebec Leukemia Cell Bank with informed consent. The project was approved by the

Research Ethics Board of the Maisonneuve-Rosemont Hospital and Université de Montréal. These samples include the complete array of phenotypic T-ALL, ranging from ETP (1 sample) to cortical T (3 samples), as previously published [105]. Transcriptome libraries were generated from 4  $\mu$ g total RNA. Sequence data obtained by paired-end sequencing (2 $\times$ 100 bp, Illumina HiSeq2000) were mapped to the mouse reference genome and analyzed as reported. RNA-seq yielded 15 Gb of mapped reads per sample, with an average of 15.2 reads per kilobase per million (RPKM). Data were log2 transformed and normalized between samples. RPKM values are taken as measures of the relative molar RNA concentration for each set of transcript. Correlation coefficients calculated for *LMO2* are shown in Fig. 6C.

Additional details for clonality analysis, co-immunoprecipitation, Luciferase assays and Notch1 sequencing are provided in S1 Protocol.

### Supporting Information

**S1 Fig.** (A) Schematic diagram of thymocyte differentiation. (B) Gating strategy for purification of thymocyte subpopulations. (C) Total cell numbers recovered from the thymi and spleens of mice transplanted with either pre-leukemic thymocytes or leukemic thymocytes from *SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice. Donor thymocytes were taken during the pre-leukemic phase (5 week-old) or at time of overt leukemia (16-20 week-old). (PDF)

**S2 Fig.** GSI does not affect the viability of OP9-DL1 stromal cells. OP9-DL1 stromal cells were cultured in the presence (0.5–5  $\mu$ M) or not of DAPT (GSI). After 4 days, the number of viable cells recovered per culture was calculated. (PDF)

**S3 Fig.** The *Notch1* oncogene collaborates with SCL-LMO1 to induce pre-leukemic cell infiltration in hematopoietic organs. (A) Mice transplanted with *SCL<sup>tg</sup>LMO1<sup>tg</sup>* or *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes were analyzed by flow cytometry for reconstitution in the spleen and BM after 3 weeks ( $10^5$  thymocytes per mouse). (B) Representative FACS profiles of donor-derived T cells (CD45.2<sup>+</sup>Thy1<sup>+</sup>) recovered in the thymus, spleen and BM of mice transplanted with *SCL<sup>tg</sup>LMO1<sup>tg</sup>* and *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* pre-leukemic thymocytes after 3 weeks. Note that the low levels of donor-derived T cells ( $<1\%$ , panel A) in the spleen and bone marrow of mice transplanted with *SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes were mature SP8 or SP4 cells whereas the thymus was repopulated to high levels (10–80%) by donor-derived immature DN and DP cells. In contrast, the spleen, bone marrow and thymus of mice transplanted with *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* pre-leukemic thymocytes were reconstituted to high levels by the same DN, ISP8 and DP cells. (C) Oncogenic *Notch1* did not modify the mean stem cell activities (MAS) of *SCL<sup>tg</sup>LMO1<sup>tg</sup>* pre-LSCs. The MAS of *SCL<sup>tg</sup>LMO1<sup>tg</sup>* and *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* pre-LSCs was calculated at  $\sim 1$  CRU. Box plots illustrate the medians together with the 25 and 75 percentiles and the extreme values in each distribution. (D) *Tcr $\beta$*  gene rearrangement signature in pre-leukemic thymocytes from *SCL<sup>tg</sup>LMO1<sup>tg</sup>*, *Notch1<sup>tg</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* mice before and after transplantation. (PDF)

**S4 Fig.** The *Notch1* oncogene confers a competitive advantage to *SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes whereas pre-TCR signalling is dispensable. (A) Representative FACS profiles of thymocytes from *Cd3 $\epsilon$* -proficient or *Cd3 $\epsilon$* -deficient WT mice. (B) DN3 *Cd3 $\epsilon$ <sup>-/-</sup>SCL<sup>tg</sup>LMO1<sup>tg</sup>* thymocytes exhibit an aberrant self-renewal activity. Serial transplantation of pre-leukemic *Cd3 $\epsilon$ <sup>-/-</sup>SCL<sup>tg</sup>L-*

*MOI*<sup>tg</sup> thymocytes ( $5 \times 10^6$ ) was into primary (I), secondary (II) and tertiary (III) recipient mice (6 to 9 mice per group) (*left panel*). The absolute numbers of donor-derived DN3 thymocytes were calculated 3 weeks after transplantation (*right panel*). (C) The *Notch1* oncogene confers a competitive advantage to *Cd3ε*<sup>-/-</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic thymocytes. Illustrated are representative FACS profiles of competition assays between *Cd3ε*<sup>-/-</sup>*Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *Cd3ε*<sup>-/-</sup>*Gfp*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> thymocytes, 3 weeks post-transplantation. Data show reconstitution (Thy1.2<sup>+</sup>CD45.2<sup>+</sup>) within the GFP<sup>+</sup> and GFP<sup>-</sup> populations, representative of each cohort of transplanted recipients. (D) *Notch1* expands the cellular targets of *SCL*-*LMO1* to DN1-4 and ISP8 but not DP cells. Pre-leukemic thymocyte subsets were purified from *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice as indicated and transplanted at  $3 \times 10^4$  cells per recipient mouse and engraftment in the thymus, le spleena and the BM was assessed 3 weeks later. (PDF)

**S5 Fig.** DN3 thymocytes express highest Notch levels and exhibit highest NOTCH1 activity. (A) Expression levels of the *Notch1* and *Notch3* genes in purified thymocyte subsets from *WT* and *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice were assessed by qRT-PCR. Data are the mean  $\pm$  SD of 3 independent experiments, after normalization to  $\beta$ -Actin. (B) The percentages of GFP<sup>+</sup> cells in thymocyte subsets from *Notch1* reporter (*TNR*<sup>tg</sup>) mice were compared by flow cytometry analysis. (PDF)

**S6 Fig.** (A) Lineage negative (LIN<sup>-</sup>) cells from *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice (CD45.2<sup>+</sup>) were transduced with either MSCV-GFP, -Hes1 and -cMyc retroviral vectors as described in Fig. 3D. Absolute number of donor-derived GFP<sup>+</sup>CD45.2<sup>+</sup> DN1, DN4 and DP thymocytes in primary mice was calculated. (B) *Hes1* RNA interference decreases the expansion of *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic thymocytes in transplanted hosts. Lineage negative (LIN<sup>-</sup>) cells from *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> mice were transduced with either sh*Hes1* lentiviral vectors or non-targeted control shRNA (shCTL) and transplanted (*upper panel*). Thymocytes were harvested and transplanted into secondary recipients. Shown are the absolute numbers of donor-derived thymocyte subsets in secondary recipient mice ( $n = 7$ , \*\*  $p < 0.001$ , *lower panel*). (PDF)

**S7 Fig.** (A) Heatmap of the 53 up-regulated genes identified by transcriptome analysis of *Cd3ε*<sup>-/-</sup> thymocytes expressing *SCL*-*LMO1* or not with the probability of false positive  $< 0.01$  (*left panel*). Comparison of this list with the TAL-1, LMO2 and *LYL1* genome binding profiles from a compendium of ChIP-seq datasets in several hematopoietic cell lines [74] (*right panel*). (B) *Lyl1* gene is associated with hematopoietic and cancer stem cell signature. The comparison of the up-regulated genes by *SCL*-*LMO1* in pre-leukemic thymocytes with published gene signatures from the GeneSig and SDB databases highlights a subset of genes that are found in hematopoietic and cancer stem cell signatures, including *Lyl1*. (PDF)

**S8 Fig.** (A) GSEA analysis of E2A-bound genes in *SCL*-*LMO1* thymocytes was analyzed as described in Fig. 4B. (B) *SCLm13* interacts with E47 but not *LMO1*. Thymocyte extracts were immunoprecipitated with the indicated antibodies (IP), followed by western blotting with the antibodies shown on the left. Note that both E47 and *LMO1* co-immunoprecipitated with *SCL* while only E47 co-immunoprecipitated with *SCLm13*. (C) The interaction between *SCL* and *LMO1* is required for *Lyl1* promoter activation. Results are expressed as fold activation of the *Lyl1* promoter (*Lyl1*-

Luc) in NIH3T3 cells co-transfected with *SCL* or *SCLm13* together with *LMO1*, *LDB1*, *E47* and *GATA1* (complex +*SCL* or *SCLm13*) relative to the reporter vector alone. The activity of this complex depends on *SCL* (compare complex + versus - *SCL*). Data were normalized to an internal control for transfection efficiency (CMV-βgal) and represent the mean  $\pm$  SD ( $n = 3$ ). (D) E protein-dependent *Ptcra* enhancer activity is similarly inhibited by *SCL* and *SCLm13*. AD10.1 DN T cells were electroporated with *Ptcra* enhancer constructs, and the MSCV vector with or without *SCL* or *SCLm13*. Results are expressed as luciferase activity relative to the minimal TATA promoter. (E) Loss of one *E2a* allele significantly decreased expression levels of E2A target genes in DN thymocytes. mRNA levels of *Cdkn2a* and *Ptcra* in purified DN thymocytes from *E2a*<sup>+/+</sup>, *E2a*<sup>+/-</sup> and *E2a*<sup>-/-</sup> mice were determined by qRT-PCR and normalized to  $\beta$ -Actin (Mean  $\pm$  SD,  $n = 3$ ).

(PDF)

**S9 Fig.** (A) Pre-leukemic DN3 thymocytes from 3-week-old donor mice of the indicated genotypes were transplanted ( $5 \times 10^4$  cells per recipient mouse). Donor-derived thymocytes (CD45.2<sup>+</sup>Thy1<sup>+</sup>) were analysed by flow cytometry 6 weeks post-transplantation. (B) Representative immunophenotypes of engrafted thymocytes of the indicated genotypes. (PDF)

**S10 Fig.** *LYL1*-*LMO1* specifically expand the DN3 cell population after transplantation. Pre-leukemic thymocytes ( $1.5 \times 10^7$  cells) from 3-week-old *LYL1*<sup>tg</sup>*LMO1*<sup>tg</sup> mice (CD45.2<sup>+</sup>) were transplanted into sub-lethally irradiated CD45.1<sup>+</sup> recipient mice. Mice were analyzed for engraftment 6 weeks post-transplantation. The expansion folds of the indicated thymocyte subsets were calculated as the ratio of the absolute numbers of donor-derived cells of each subset recovered from the thymus of transplanted mice over the absolute numbers present in the initial inoculum. (PDF)

**S11 Fig.** Heat map of gene expression profiles in pediatric T-ALL patient samples [38] obtained by RT-PCR. (PDF)

**S1 Table** Absence of *Notch1* activating mutations in *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic thymocytes. The exons 26, 27 and 34 of the *Notch1* gene from *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> and *Notch1*<sup>tg</sup>*SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> pre-leukemic thymocytes before and after transplantation were sequenced. *SCL*<sup>tg</sup>*LMO1*<sup>tg</sup> leukemic cells were used as a positive control. Provided in excel file. (XLS)

**S2 Table** List of NOTCH1-bound genes responding to GSI that are upregulated during thymocyte differentiation. Gene expression data from the Immgen project were collected. Listed are genes that increase by more than 1.3-fold at each transitional stage and exhibit NOTCH1-bound peaks within 2 kb of the transcription start sites [68]. Peaks that are common in 2 murine T-ALL cell lines were retained for this analysis. Provided in excel file. (XLS)

**S3 Table** List of genes differentially expressed between *Cd3ε*<sup>-/-</sup> thymocytes expressing or not the *SCL* and *LMO1* oncogenes assessed by a probability of false positive threshold (Pfp) smaller than 0.01. The comparison of this list with the TAL-1/LMO2 genome binding profiles from a compendium of ChIP-seq datasets in several hematopoietic cell lines [74], identified 9 genes (in bold) that are presumed direct *SCL* and *LMO2* targets. Provided in excel file. (XLS)

**S4 Table** Significant signature enrichment in differentially expressed genes (adjusted p values  $\leq 0.05$ ). Provided in excel file. (XLS)

**S5 Table** Sequences of oligonucleotide primers used for TaqMan Real-time quantitative PCR, *TCR $\beta$*  gene rearrangements, chromatin immunoprecipitation and for Sanger sequencing of exons 26, 27 and 34 of the *Notch1* gene. Provided in excel file. (XLS)

**S1 Protocol** Additional details for clonality analysis, co-immunoprecipitation, luciferase assays and Notch1 sequencing are provided in S1 Protocol. (DOCX)

## References

- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 367: 645–648.
- Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, et al. (2013) Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. *Cancer Res* 73: 1037–1045.
- Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 3: 730–737.
- Jordan CT (2009) Cancer stem cells: controversial or just misunderstood? *Cell Stem Cell* 4: 203–205.
- Vicente-Duenas C, Romero-Camarero I, Cobaleda C, Sanchez-Garcia I (2013) Function of oncogenes in cancer development: a changing paradigm. *EMBO J* 32: 1502–1513.
- Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. *Nat Rev Cancer* 12: 133–143.
- Greaves M, Maley CC (2012) Clonal evolution in cancer. *Nature* 481: 306–313.
- Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, et al. (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. *Nature* 442: 818–822.
- McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, et al. (2010) The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. *Science* 327: 879–883.
- Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, et al. (2008) Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. *Science* 319: 336–339.
- Bhandoola A, Sambandam A (2006) From stem cell to T cell: one route or many? *Nat Rev Immunol* 6: 117–126.
- Martins VC, Ruggiero E, Schlenner SM, Madan V, Schmidt M, et al. (2012) Thymus-autonomous T cell development in the absence of progenitor import. *J Exp Med* 209: 1409–1417.
- Zhang JA, Mortazavi A, Williams BA, Wold BJ, Rothenberg EV (2012) Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity. *Cell* 149: 467–482.
- Ciofani M, Schmitt TM, Ciofani A, Michie AM, Cuburu N, et al. (2004) Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. *J Immunol* 172: 5230–5239.
- Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* 306: 269–271.
- O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, et al. (2006) Activating Notch1 mutations in mouse models of T-ALL. *Blood* 107: 781–785.
- Tremblay M, Tremblay CS, Herblot S, Aplan PD, Hebert J, et al. (2010) Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. *Genes Dev* 24: 1093–1105.
- Bigas A, Espinosa L (2012) Hematopoietic stem cells: to be or Notch to be. *Blood* 119: 3226–3235.
- Koch U, Lehal R, Radtke F (2013) Stem cells living with a Notch. *Development* 140: 689–704.
- Chiang MY, Shestova O, Xu L, Aster JC, Pear WS (2012) Divergent effects of supraphysiological Notch signals on leukemia stem cells and hematopoietic stem cells. *Blood*.
- Armstrong F, de la Grange PB, Gerby B, Rouyez MC, Calvo J, et al. (2009) NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. *Blood* 113: 1730–1740.
- Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, et al. (2011) Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. *Leukemia* 25: 1249–1258.
- Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, et al. (2011) Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. *Blood* 118: 1579–1590.
- Wendorff AA, Koch U, Wunderlich FT, Wirth S, Dubey C, et al. (2010) Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. *Immunity* 33: 671–684.
- Dudley DD, Wang HC, Sun XH (2009) Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. *PLoS One* 4: e6678.
- D'Altri T, Gonzalez J, Aifantis I, Espinosa L, Bigas A (2011) Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia. *Cell Cycle* 10: 1031–1036.
- Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, et al. (2006) c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. *Genes Dev* 20: 2096–2109.
- Steininger A, Mobs M, Ullmann R, Kochert K, Kreher S, et al. (2011) Genomic loss of the putative tumor suppressor gene E2A in human lymphoma. *J Exp Med* 208: 1585–1593.
- Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, et al. (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc Natl Acad Sci U S A* 103: 18261–18266.
- Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, et al. (2008) Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. *J Clin Invest* 118: 3181–3194.
- Swiers G, Patient R, Loose M (2006) Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. *Dev Biol* 294: 525–540.
- Reynaud D, Ravet E, Titeux M, Mazurier F, Renia L, et al. (2005) SCL/TAL1 expression level regulates human hematopoietic stem cell self-renewal and engraftment. *Blood* 106: 2318–2328.
- Lacombe J, Herblot S, Rojas-Sutterlin S, Haman A, Barakat S, et al. (2010) Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. *Blood* 115: 792–803.
- Souroullas GP, Salmon JM, Sablitzky F, Curtis DJ, Goodell MA (2009) Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. *Cell Stem Cell* 4: 180–186.
- Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, et al. (1996) The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. *Cell* 86: 47–57.
- Schlaeger TM, Schuh A, Flitter S, Fisher A, Mikkola H, et al. (2004) Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1. *Mol Cell Biol* 24: 7491–7502.
- Lecuyer E, Lariviere S, Sincennes MC, Haman A, Lahli R, et al. (2007) Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction. *J Biol Chem* 282: 33649–33658.
- Ferrando AA, Neuberger DS, Staunton J, Loh ML, Huard C, et al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell* 1: 75–87.
- McGuire EA, Rintoul CE, Sclar GM, Korsmeyer SJ (1992) Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma. *Mol Cell Biol* 12: 4186–4196.
- Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, et al. (1997) An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. *EMBO J* 16: 2408–2419.
- Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, et al. (1996) Protein dimerization between Lmo2 (Rbtl2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. *Embo J* 15: 1021–1027.
- Hsu HL, Wadman I, Tsan JT, Baer R (1994) Positive and negative transcriptional control by the TAL1 helix-loop-helix protein. *Proc Natl Acad Sci U S A* 91: 5947–5951.
- Park ST, Sun XH (1998) The Tal1 oncoprotein inhibits E47-mediated transcription. Mechanism of inhibition. *J Biol Chem* 273: 7030–7037.
- Chervinsky DS, Zhao XF, Lam DH, Ellsworth M, Gross KW, et al. (1999) Disordered T-cell development and T-cell malignancies in SCL LMO1 double-

## Acknowledgments

We thank Danièle Mathieu (INSERM, Marseille, France) for the anti-SCL antibody, Danièle Gagné and Gael Dulude for assistance with flow cytometry, Véronique Litalien for mouse husbandry, André Haman with co-culture assays, Alycia Try and Ngoc Vo for promoter-enhancer assays, Pierre Chagnon and Raphaëlle Lambert for sequencing.

## Author Contributions

Conceived and designed the experiments: BG DFTV MT CST EL TH. Performed the experiments: BG CST MT DFTV SRS SH. Analyzed the data: BG CST MT DFTV SRS SL SH GS JH TH. Contributed reagents/materials/analysis tools: EL GS JH. Wrote the paper: BG CST MT DFTV EL GS TH.

- transgenic mice: parallels with E2A-deficient mice. *Mol Cell Biol* 19: 5025–5035.
45. Yan W, Young AZ, Soares VC, Kelley R, Benezra R, et al. (1997) High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. *Mol Cell Biol* 17: 7317–7327.
  46. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T (2000) SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. *Nat Immunol* 1: 138–144.
  47. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M (2004) TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. *Cancer Cell* 5: 587–596.
  48. Murre C (2005) Helix-loop-helix proteins and lymphocyte development. *Nat Immunol* 6: 1079–1086.
  49. Kee BL (2009) E and ID proteins branch out. *Nat Rev Immunol* 9: 175–184.
  50. Herblot S, Aplan PD, Hoang T (2002) Gradient of E2A activity in B-cell development. *Mol Cell Biol* 22: 886–900.
  51. Goardon N, Schuh A, Hajar I, Ma X, Jouault H, et al. (2002) Ectopic expression of TAL-1 protein in Ly-6E.1-hlal-1 transgenic mice induces defects in B- and T-lymphoid differentiation. *Blood* 100: 491–500.
  52. Robb L, Rasko JE, Bath ML, Strasser A, Begley CG (1995) scl, a gene frequently activated in human T cell leukaemia, does not induce lymphomas in transgenic mice. *Oncogene* 10: 205–209.
  53. Kelliher MA, Seldin DC, Leder P (1996) Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. *Embo J* 15: 5160–5166.
  54. Aifantis I, Raetz E, Buonamici S (2008) Molecular pathogenesis of T-cell leukaemia and lymphoma. *Nat Rev Immunol* 8: 380–390.
  55. Kim D, Peng XC, Sun XH (1999) Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. *Mol Cell Biol* 19: 8240–8253.
  56. Van Vlierberghe P, Ferrando A (2012) The molecular basis of T cell acute lymphoblastic leukemia. *J Clin Invest* 122: 3398–3406.
  57. Ono Y, Fukuhara N, Yoshie O (1998) TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. *Mol Cell Biol* 18: 6939–6950.
  58. Lecuyer E, Herblot S, Saint-Denis M, Martin R, Begley CG, et al. (2002) The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. *Blood* 100: 2430–2440.
  59. Kusy S, Gerby B, Goardon N, Gault N, Ferri F, et al. (2010) NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia. *J Exp Med* 207: 2141–2156.
  60. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, et al. (2012) Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell* 22: 209–221.
  61. McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, et al. (2013) Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. *Blood*.
  62. McMurray HR, Sampson ER, Compitello G, Kinsey C, Newman L, et al. (2008) Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. *Nature* 453: 1112–1116.
  63. Ashton JM, Bally M, Neering SJ, Hassane DC, Cowley G, et al. (2012) Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. *Cell Stem Cell* 11: 359–372.
  64. Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 368: 2059–2074.
  65. Kalender Atak Z, Gianfelici V, Hulselms G, De Keersmaecker K, Devasia AG, et al. (2013) Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. *PLoS Genet* 9: e1003997.
  66. Schmitt TM, Zuniga-Pflucker JC (2002) Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. *Immunity* 17: 749–756.
  67. Tan JB, Visan I, Yuan JS, Guidos CJ (2005) Requirement for Notch1 signals at sequential early stages of intrathymic T cell development. *Nat Immunol* 6: 671–679.
  68. Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, et al. (2011) Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. *Proc Natl Acad Sci U S A* 108: 14908–14913.
  69. Aster JC, Pear WS, Blacklow SC (2008) Notch signaling in leukemia. *Annu Rev Pathol* 3: 587–613.
  70. Deneault E, Cellot S, Faubert A, Laverdure JP, Frechette M, et al. (2009) A functional screen to identify novel effectors of hematopoietic stem cell activity. *Cell* 137: 369–379.
  71. Rossi L, Lin KK, Boles NC, Yang L, King KY, et al. (2012) Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice. *Cell Stem Cell* 11: 302–317.
  72. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, et al. (2006) Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. *Mol Cell Biol* 26: 8022–8031.
  73. Kunisato A, Chiba S, Nakagami-Yamaguchi E, Kumano K, Saito T, et al. (2003) HES-1 preserves purified hematopoietic stem cells ex vivo and accumulates side population cells in vivo. *Blood* 101: 1777–1783.
  74. Hannah R, Joshi A, Wilson NK, Kinston S, Gottgens B (2011) A compendium of genome-wide hematopoietic transcription factor maps supports the identification of gene regulatory control mechanisms. *Exp Hematol* 39: 531–541.
  75. Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, et al. (2010) Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell* 7: 532–544.
  76. Lecuyer E, Hoang T (2004) SCL: from the origin of hematopoiesis to stem cells and leukemia. *Exp Hematol* 32: 11–24.
  77. Ikawa T, Kawamoto H, Goldrath AW, Murre C (2006) E proteins and Notch signaling cooperate to promote T cell lineage specification and commitment. *J Exp Med* 203: 1329–1342.
  78. Miyazaki K, Miyazaki M, Murre C (2014) The establishment of B versus T cell identity. *Trends Immunol* 35: 205–210.
  79. Bain G, Quong MW, Soloff RS, Hedrick SM, Murre C (1999) Thymocyte maturation is regulated by the activity of the helix-loop-helix protein, E47. *J Exp Med* 190: 1605–1616.
  80. Zhuang Y, Cheng P, Weintraub H (1996) B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB. *Mol Cell Biol* 16: 2898–2905.
  81. Deleuze V, El-Hajj R, Chalhoub E, Dohet C, Pinet V, et al. (2012) Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells. *PLoS One* 7: e40484.
  82. Zohren F, Souroullas GP, Luo M, Gerdemann U, Imperato MR, et al. (2012) The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors. *Nat Immunol* 13: 761–769.
  83. Homminga I, Pieters R, Langerak AW, de Rooij JJ, Stubbs A, et al. (2011) Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. *Cancer Cell* 19: 484–497.
  84. Smith S, Tripathi R, Goodings C, Cleveland S, Mathias E, et al. (2014) LIM Domain Only-2 (LMO2) Induces T-Cell Leukemia by Two Distinct Pathways. *PLoS One* 9: e85883.
  85. Homminga I, Vuerhard MJ, Langerak AW, Buijs-Gladdines J, Pieters R, et al. (2012) Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements. *Haematologica* 97: 258–261.
  86. Giambra V, Jenkins CR, Wang H, Lam SH, Shevchuk OO, et al. (2012) NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-theta and reactive oxygen species. *Nat Med* 18: 1693–1698.
  87. King B, Trimarchi T, Reavie L, Xu L, Mullenders J, et al. (2013) The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell* 153: 1552–1566.
  88. Maillard I, Koch U, Dumortier A, Shestova O, Xu L, et al. (2008) Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. *Cell Stem Cell* 2: 356–366.
  89. Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ (2010) Functions of notch signaling in the immune system: consensus and controversies. *Annu Rev Immunol* 28: 343–365.
  90. Phelan JD, Saba I, Zeng H, Kosan C, Messer MS, et al. (2013) Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors. *PLoS Genet* 9: e1003713.
  91. Tzoneva G, Ferrando AA (2012) Recent advances on NOTCH signaling in T-ALL. *Curr Top Microbiol Immunol* 360: 163–182.
  92. De Obaldia ME, Bell JJ, Wang X, Harley C, Yashiro-Ohtani Y, et al. (2013) T cell development requires constraint of the myeloid regulator C/EBP-alpha by the Notch target and transcriptional repressor Hes1. *Nat Immunol* 14: 1277–1284.
  93. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, et al. (2008) Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. *Cell Stem Cell* 3: 611–624.
  94. Baena E, Ortiz M, Martinez AC, de Alboran IM (2007) c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21. *Exp Hematol* 35: 1333–1343.
  95. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, et al. (2004) c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. *Genes Dev* 18: 2747–2763.
  96. Reavie L, Della Gatta G, Crusio K, Aranda-Orgilles B, Buckley SM, et al. (2010) Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. *Nat Immunol* 11: 207–215.
  97. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, et al. (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. *J Exp Med* 204: 1813–1824.
  98. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S (2010) Promotion of direct reprogramming by transformation-deficient Myc. *Proc Natl Acad Sci U S A* 107: 14152–14157.
  99. Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, et al. (2014) c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. *Blood* 123: 1040–1050.
  100. Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, et al. (2014) Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. *Oncotarget* 5: 3168–3172.
  101. Smith IJ, Curtis JE, Messner HA, Senn JS, Furthmayr H, et al. (1983) Lineage infidelity in acute leukemia. *Blood* 61: 1138–1145.

102. Ischenko I, Zhi J, Moll UM, Nemajero A, Petrenko O (2013) Direct reprogramming by oncogenic Ras and Myc. *Proc Natl Acad Sci U S A* 110: 3937–3942.
103. Chiu PP, Jiang H, Dick JE (2010) Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. *Blood* 116: 5268–5279.
104. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, et al. (2005) HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). *Blood* 106: 274–286.
105. Simon C, Chagraoui J, Kros J, Gendron P, Wilhelm B, et al. (2012) A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. *Genes Dev* 26: 651–656.
106. Nagel S, Venturini L, Meyer C, Kaufmann M, Scherr M, et al. (2010) Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. *Leuk Res* 34: 521–528.
107. Zhuang Y, Kim CG, Bartelmez S, Cheng P, Groudine M, et al. (1992) Helix-loop-helix transcription factors E12 and E47 are not essential for skeletal or cardiac myogenesis, erythropoiesis, chondrogenesis, or neurogenesis. *Proc Natl Acad Sci U S A* 89: 12132–12136.
108. Malissen M, Gillet A, Ardouin L, Bouvier G, Trucy J, et al. (1995) Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. *EMBO J* 14: 4641–4653.
109. Zhumabekov T, Corbella P, Tolaini M, Kioussis D (1995) Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. *J Immunol Methods* 185: 133–140.
110. Greaves DR, Wilson FD, Lang G, Kioussis D (1989) Human CD2 3'-flanking sequences confer high-level, T cell-specific, position-independent gene expression in transgenic mice. *Cell* 56: 979–986.
111. Harrison DE, Jordan CT, Zhong RK, Astle CM (1993) Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. *Exp Hematol* 21: 206–219.
112. Ema H, Nakauchi H (2000) Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. *Blood* 95: 2284–2288.
113. Tanigawa T, Elwood N, Metcalf D, Cary D, DeLuca E, et al. (1993) The SCL gene product is regulated by and differentially regulates cytokine responses during myeloid leukemic cell differentiation. *Proc Natl Acad Sci U S A* 90: 7864–7868.
114. Trickett A, Kwan YL (2003) T cell stimulation and expansion using anti-CD3/CD28 beads. *J Immunol Methods* 275: 251–255.
115. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy—analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 20: 307–315.
116. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. *FEBS Lett* 573: 83–92.
117. Salmon-Divon M, Dvinge H, Tammoja K, Bertone P (2010) PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci. *BMC Bioinformatics* 11: 415.
118. Tremblay M, Herblot S, Lecuyer E, Hoang T (2003) Regulation of pT alpha gene expression by a dosage of E2A, HEB, and SCL. *J Biol Chem* 278: 12680–12687.
119. Lacombe J, Kros J, Tremblay M, Gerby B, Martin R, et al. (2013) Genetic interaction between Kit and Scl. *Blood* 122: 1150–1161.
120. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, et al. (2010) ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. *Bioinformatics* 26: 2438–2444.